[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2067
1. Wei LC, Shi M, Cao R, Chen LW, Chan YS: Nestin small interfering RNA (siRNA) reduces cell growth in cultured astrocytoma cells. Brain Res; 2008 Feb 27;1196:103-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin small interfering RNA (siRNA) reduces cell growth in cultured astrocytoma cells.
  • Growing evidence has shown that abundant expression of nestin also occurs in both pathological glial-derived tumor cells and reactive astrocytes in various CNS injuries, implying that nestin may play a crucial role in cell growth or proliferation of astrocyte-derived tumor cells.
  • In the present study, we have investigated the possible role of nestin expression in cell growth or survival of CNS tumor cells by using novel small interfering RNA (siRNA) method in cell culture of rat astrocytoma C6 cell line.
  • The nestin expression and cell growth of the cultured astrocytoma cells were examined after nestin siRNA duplex was delivered by cell transfection for 6 h and cell culture was maintained for 48 h.
  • It revealed an effective suppression influence of nestin siRNA on cell growth of cultured astrocytoma cells in a dose-dependent manner.
  • This study has provided in vitro evidence that nestin siRNA can effectively block nestin expression and reduce cell growth of the cultured C6 astrocytoma cells, strongly suggesting that nestin siRNA-induced suppression of tumor cell growth may provide a potential novel clinical therapy against CNS astroglioma events.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / physiopathology. Intermediate Filament Proteins / genetics. Nerve Tissue Proteins / genetics. RNA, Small Interfering / metabolism
  • [MeSH-minor] Analysis of Variance. Animals. Cell Count. Cell Line, Tumor. Dose-Response Relationship, Drug. Gene Expression Regulation / drug effects. Glial Fibrillary Acidic Protein / metabolism. Nestin. Rats

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18234160.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / Nerve Tissue Proteins; 0 / Nes protein, rat; 0 / Nestin; 0 / RNA, Small Interfering
  •  go-up   go-down


2. Ng YT, Bristol RE, Schrader DV, Smith KA: The role of neurosurgery in status epilepticus. Neurocrit Care; 2007;7(1):86-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT AND METHODS: Subdural grid electrodes were used to record cortical discharges and guide tumor resection involving eloquent cortex and multiple subpial transections in a 48-year-old man with left hemiparesis in status epilepticus.
  • Following tumor removal, multiple subpial transections were subsequently performed over large areas of the motor and sensory strips and successfully resolved the status epilepticus.
  • [MeSH-minor] Astrocytoma / complications. Astrocytoma / surgery. Brain Neoplasms / complications. Brain Neoplasms / surgery. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Status epilepticus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Palliat Med. 2004 Feb;7(1):85-8 [15000791.001]
  • [Cites] Seizure. 2001 Jul;10(5):382-5 [11488652.001]
  • [Cites] J Neurosurg. 2006 Nov;105(5 Suppl):378-81 [17328261.001]
  • [Cites] Surg Neurol. 2005 Aug;64(2):170-3 [16051017.001]
  • [Cites] Epileptic Disord. 2002 Sep;4(3):203-8 [12446223.001]
  • [Cites] Neurology. 1990 May;40(5 Suppl 2):9-13 [2185441.001]
  • [Cites] Arch Neurol. 1977 May;34(5):266-75 [404996.001]
  • [Cites] Arch Neurol. 1993 Jul;50(7):695-700 [8323470.001]
  • [Cites] Epilepsia. 2003 Mar;44(3):468-71 [12614407.001]
  • [Cites] Pediatr Neurosurg. 2001 Apr;34(4):190-2 [11359111.001]
  • [Cites] Epilepsia. 2002 Feb;43(2):141-5 [11903459.001]
  • [Cites] Epilepsia. 1992 May-Jun;33(3):546-9 [1592035.001]
  • [Cites] Eur J Neurol. 2004 Dec;11(12):800-10 [15667410.001]
  • [Cites] Seizure. 2002 Oct;11(7):437-41 [12237069.001]
  • [Cites] J Clin Neurophysiol. 1995 Jul;12(4):326-42 [7560021.001]
  • [Cites] Epilepsia. 1999 Jan;40(1):120-2 [9924914.001]
  • [Cites] Epilepsia. 2005 Apr;46(4):592-4 [15816959.001]
  • [Cites] N Engl J Med. 1998 Sep 17;339(12):792-8 [9738086.001]
  • [Cites] Arch Neurol. 2006 Jun;63(6):895-901 [16769873.001]
  • [Cites] J Neurosurg. 1989 Feb;70(2):231-9 [2492335.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 Jul;65(1):137-8 [9667583.001]
  • [Cites] Epilepsy Res. 2001 Jul;46(1):33-8 [11395286.001]
  • [Cites] Neurology. 2005 Feb 8;64(3):567-70 [15699401.001]
  • [Cites] Epilepsia. 2004 Aug;45(8):1001-4 [15270771.001]
  • [Cites] Neurocrit Care. 2006;4(1):35-46 [16498194.001]
  • [Cites] Brain. 1996 Apr;119 ( Pt 2):393-407 [8800935.001]
  • (PMID = 17657660.001).
  • [ISSN] 1541-6933
  • [Journal-full-title] Neurocritical care
  • [ISO-abbreviation] Neurocrit Care
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Ishihara R, Katayama Y, Watanabe T, Yoshino A, Fukushima T, Sakatani K: Quantitative spectroscopic analysis of 5-aminolevulinic acid-induced protoporphyrin IX fluorescence intensity in diffusely infiltrating astrocytomas. Neurol Med Chir (Tokyo); 2007 Feb;47(2):53-7; discussion 57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ratio of the peak emission intensity to reflected excitation intensity or fluorescence intensity ratio was less than 0.001 for all 36 non-tumor tissues.
  • [MeSH-major] Astrocytoma / chemistry. Astrocytoma / pathology. Brain Neoplasms / chemistry. Brain Neoplasms / pathology. Protoporphyrins / analysis
  • [MeSH-minor] Aged. Aminolevulinic Acid. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Photosensitizing Agents. Spectrometry, Fluorescence

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317941.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


Advertisement
4. Ferletta M, Uhrbom L, Olofsson T, Pontén F, Westermark B: Sox10 has a broad expression pattern in gliomas and enhances platelet-derived growth factor-B--induced gliomagenesis. Mol Cancer Res; 2007 Sep;5(9):891-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a previously published insertional mutagenesis screen for candidate brain tumor genes in the mouse using a Moloney mouse leukemia virus encoding platelet-derived growth factor (PDGF)-B, the Sox10 gene was tagged in five independent tumors.
  • All Moloney murine leukemia virus/PDGFB tumors had a high protein expression of Sox10 independently of malignant grade or tumor type.
  • Combined infection of RCAS-SOX10 and RCAS-PDGFB in wild-type Ntv-a mice yielded a tumor frequency of 12%, and in Ntv-a Arf-/- mice the tumor frequency was 30%.
  • [MeSH-major] Brain Neoplasms / genetics. DNA-Binding Proteins / genetics. Gene Expression Regulation, Neoplastic. Glioma / genetics. Glioma / pathology. High Mobility Group Proteins / genetics. Platelet-Derived Growth Factor / physiology. Transcription Factors / genetics
  • [MeSH-minor] Animals. Astrocytoma / genetics. Chickens. Glioblastoma / genetics. Humans. Intermediate Filament Proteins / genetics. Melanoma / genetics. Mice. Nerve Tissue Proteins / genetics. Nestin. Promoter Regions, Genetic. SOXE Transcription Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17855658.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / High Mobility Group Proteins; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / Platelet-Derived Growth Factor; 0 / SOX10 protein, human; 0 / SOXE Transcription Factors; 0 / Sox10 protein, mouse; 0 / Transcription Factors
  •  go-up   go-down


5. Lin KC, Cheng TJ, Yung JM, Kuo JR: Malignant astrocytoma following radiation for nasopharyngeal carcinoma: case report and review of the literature. Acta Neurol Taiwan; 2007 Mar;16(1):27-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant astrocytoma following radiation for nasopharyngeal carcinoma: case report and review of the literature.
  • A 32-year-old woman developed malignant astrocytoma 3 years after radiotherapy for nasopharnygeal carcinoma (NPC).
  • Introduction of brain malignancy induction after external beam radiation for craniopharyngioma, pituitary adenoma, or meningioma has been previously reported.
  • The theoretical risk of tumor induction in neural tissues, following radiotherapy by low-dose radiation has been verified, but the association of radiation-induced brain malignancy and NPC is extremely rare.
  • [MeSH-major] Astrocytoma / etiology. Brain Neoplasms / etiology. Nasopharyngeal Neoplasms / radiotherapy. Neoplasms, Radiation-Induced / etiology. Radiotherapy / adverse effects


6. Kano H, Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD: Stereotactic radiosurgery for pilocytic astrocytomas part 1: outcomes in adult patients. J Neurooncol; 2009 Nov;95(2):211-218
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Localized solid tumor progression was seen in two patients.
  • The progression free survival after SRS (including tumor growth and cyst enlargement) for the entire series was 83.9%, 31.5% and 31.5% at 1, 3 and 5 years, respectively.
  • Unresectable pilocytic astrocytomas that are located in critical or deep areas of the brain require additional management approaches.
  • Delayed cyst progression contributes to late loss of tumor control.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Radiosurgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2002 Jul;97(1):56-64 [12134933.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1335-42 [8339223.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Apr;18(4):971-3 [2323983.001]
  • [Cites] J Neurosurg. 1973 Dec;39(6):777-9 [4759666.001]
  • [Cites] J Neurooncol. 2006 Jan;76(1):55-8 [16132503.001]
  • [Cites] Br J Neurosurg. 2004 Dec;18(6):613-6 [15799194.001]
  • [Cites] Br J Ophthalmol. 1969 Dec;53(12):793-8 [5386369.001]
  • [Cites] J Neurosurg. 2003 Jun;98(6):1170-4 [12816259.001]
  • [Cites] Cancer. 1985 Oct 1;56(7 Suppl):1841-6 [4027923.001]
  • [Cites] J Neurosurg. 2002 Dec;97(5 Suppl):677-80 [12507119.001]
  • [Cites] Cancer. 2007 Dec 15;110(12 ):2799-808 [17973253.001]
  • [Cites] Pediatr Neurosurg. 1996 Sep;25(3):109-15 [9144708.001]
  • [Cites] Neurosurgery. 1994 Jan;34(1):68-78 [8121571.001]
  • [Cites] Acta Neurochir (Wien). 1986;81(1-2):11-26 [3728086.001]
  • [Cites] Neurosurgery. 1990 Feb;26(2):242-6; discussion 246-7 [2308672.001]
  • [Cites] Neurosurg Rev. 1990;13(4):315-20 [2280843.001]
  • [Cites] Arch Neurol. 1968 Jan;18(1):14-9 [5634368.001]
  • [Cites] J Neurosurg. 1985 Sep;63(3):382-6 [4020465.001]
  • [Cites] Acta Neurochir (Wien). 1986;81(3-4):90-3 [3751698.001]
  • [Cites] Arch Neurol. 1971 Feb;24(2):125-35 [5540377.001]
  • [Cites] Radiology. 1993 Oct;189(1):221-5 [8372197.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):161-8 [17347491.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):964-71 [8134009.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1153-60 [15001258.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Apr;18(4):815-8 [2323970.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):856-69 [8334640.001]
  • [Cites] Pediatr Neurosurg. 1990-1991;16(4-5):219-21 [2135190.001]
  • [Cites] Childs Brain. 1983;10(2):79-91 [6839871.001]
  • (PMID = 19468691.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Davies N, Wilson BC: Interstitial in vivo ALA-PpIX mediated metronomic photodynamic therapy (mPDT) using the CNS-1 astrocytoma with bioluminescence monitoring. Photodiagnosis Photodyn Ther; 2007 Sep;4(3):202-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interstitial in vivo ALA-PpIX mediated metronomic photodynamic therapy (mPDT) using the CNS-1 astrocytoma with bioluminescence monitoring.
  • BACKGROUND: We report the first truly metronomic delivery of photodynamic therapy using the rat-derived CNS-1 astrocytoma, a model with close histopathology with human brain tumours.
  • Tumour burden before and after mPDT treatment was determined using bioluminescence imaging (BLI).
  • The reduction or elimination of tumour was confirmed using BLI and corroborated by histology.
  • Additional studies showed that 24 and 48h continuous mPDT illumination had the capability to delay tumour re-growth by a period corresponding to approximately two doubling times.
  • Animals given 4-day mPDT did not show any signs of tumour re-growth via BLI at 26 days post-tumour implantation.
  • CONCLUSIONS: In summary, these results demonstrate the feasibility of delivering mPDT for extended periods, as well as its potential as a treatment for small brain tumours.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25047439.001).
  • [ISSN] 1572-1000
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


8. Neurath KM, Keough MP, Mikkelsen T, Claffey KP: AMP-dependent protein kinase alpha 2 isoform promotes hypoxia-induced VEGF expression in human glioblastoma. Glia; 2006 May;53(7):733-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor cells respond to hypoxic stress by upregulating a variety of genes involved in glucose uptake, glycolysis, and angiogenesis, all essential to maintaining nutrient availability and intracellular ATP levels.
  • Immunohistochemistry analysis of human astrocytoma/glioma samples revealed AMPKalpha2 present in high grade gliomas within hypoxic pseudopalisading microenvironments.
  • These data suggest that prolonged hypoxia promotes the expression and functional activation of AMPKalpha2 and VEGF production in glioma cell lines and glioblastoma multiform tumors, thus contributing to tumor survival and angiogenesis in high grade human gliomas.
  • [MeSH-major] Brain Neoplasms / metabolism. Cell Hypoxia / physiology. Glioblastoma / metabolism. Hypoxia-Inducible Factor 1 / metabolism. Multienzyme Complexes / metabolism. Oxidative Stress / physiology. Protein-Serine-Threonine Kinases / metabolism. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] AMP-Activated Protein Kinases. Cell Line, Tumor. Cell Proliferation. Cell Survival / physiology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Down-Regulation / physiology. Enzyme Inhibitors / pharmacology. Humans. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / metabolism. Protein Isoforms / genetics. Protein Isoforms / metabolism. RNA Interference. RNA, Messenger / metabolism. Transcriptional Activation / physiology. Tubercidin / analogs & derivatives. Tubercidin / pharmacology

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16518831.001).
  • [ISSN] 0894-1491
  • [Journal-full-title] Glia
  • [ISO-abbreviation] Glia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-064436
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Hypoxia-Inducible Factor 1; 0 / Multienzyme Complexes; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; 24386-93-4 / 5-iodotubercidin; EC 2.7.11.1 / AMP-Activated Protein Kinases; EC 2.7.11.1 / PRKAA2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; M351LCX45Y / Tubercidin
  •  go-up   go-down


9. Bayrakli F, Dinçer A, Sav A, Vardareli E, Peker S: Late brain stem radionecrosis seventeen years after fractionated radiotherapy. Turk Neurosurg; 2009 Apr;19(2):182-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late brain stem radionecrosis seventeen years after fractionated radiotherapy.
  • The appearance of a new lesion several years after radiation treatment for a primary brain tumor may represent different kind of pathologies.
  • We present a 24-year-old patient who suffered from right-sided hemiparesis and ataxic gait with a history of an operation due to left frontoparieal grade II fibrillary astrocytoma and fractioned radiotherapy.
  • His cranial MRI study showed heterogeneous signal intensity of brain stem radionecrosis in the pons spreading through the mesencephalon and left brachium pontis.
  • The leading diagnosis was high-grade glial tumor.
  • Tissue sampling for histopathological examination is mandatory for definite diagnosis and correct treatment of the disease.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Brain Stem / pathology. Radiation Injuries / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19431132.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


10. Tamura Y, Kuroiwa T, Kajimoto Y, Miki Y, Miyatake S, Tsuji M: Endoscopic identification and biopsy sampling of an intraventricular malignant glioma using a 5-aminolevulinic acid-induced protoporphyrin IX fluorescence imaging system. Technical note. J Neurosurg; 2007 Mar;106(3):507-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic identification and biopsy sampling of an intraventricular malignant glioma using a 5-aminolevulinic acid-induced protoporphyrin IX fluorescence imaging system. Technical note.
  • Several neurosurgical studies have provided descriptions of the utility of fluorescence-guided tumor resection using a microscope.
  • However, fluorescence-guided endoscopic detection of a deep-seated brain tumor has not yet been reported.
  • The authors report their experience with an endoscopic biopsy procedure for a malignant glioma within the third ventricle using a 5-aminolevulinic acid (5-ALA)-induced protoporphyrin IX fluorescence imaging system.
  • A 5-ALA-induced fluorescence image of an intraventricular tumor is barely visible with the typical fluorescence endoscopic system used in other clinical fields because the intensity of excitation light at wavelengths of 390 to 405 nm through a cut-off filter is too weak to delineate a brain tumor.
  • A 5-ALA-induced fluorescence endoscopy performed using this system allowed the intraventricular tumor to be clearly visualized as a red fluorescent lesion.
  • Several biopsy specimens obtained from the fluorescent lesion provided a definitive histological diagnosis.
  • The results indicate that this endoscopic system is useful in detecting an intraventricular fluorescent tumor.
  • [MeSH-major] Astrocytoma / surgery. Biopsy / methods. Brain Neoplasms / surgery. Fluorescence. Neuroendoscopy / methods. Surgery, Computer-Assisted / methods

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367078.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


11. Tilleul P, Brignone M, Hassani Y, Taillandier L, Taillibert S, Cartalat-Carel S, Borget I, Chinot O: [Prescription guidebook for temozolomide usage in brain tumors]. Bull Cancer; 2009 May;96(5):579-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prescription guidebook for temozolomide usage in brain tumors].
  • Malignant gliomas are the most frequent primary brain tumors in adults.
  • It is indicated in newly diagnosed glioblastoma multiform as well as in recurrent or progressive malignant gliomas, such as glioblastoma multiform or anaplastic astrocytoma.
  • However, temozolomide is also used, off label, in other clinical situations and the main objective of this study was to establish recommendations and guidelines for relevant prescriptions of temozolomide in primary brain tumors and brain metastasis in adults.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioma / drug therapy
  • [MeSH-minor] Age Factors. Astrocytoma / drug therapy. Drug Administration Schedule. Drug Labeling. Glioblastoma / drug therapy. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467988.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Practice Guideline; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 55
  •  go-up   go-down


12. Shrestha P, Saito T, Hama S, Arifin MT, Kajiwara Y, Yamasaki F, Hidaka T, Sugiyama K, Kurisu K: Geminin: a good prognostic factor in high-grade astrocytic brain tumors. Cancer; 2007 Mar 1;109(5):949-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geminin: a good prognostic factor in high-grade astrocytic brain tumors.
  • For this study, the authors investigated geminin expression in high-grade astrocytic tumors, including anaplastic astrocytoma (AA) and glioblastoma multiforme (GBM), with a view to predicting clinical outcomes on this basis in patients with these malignant brain tumors.
  • METHODS: Immunohistochemistry was used to detect geminin expression in 51 patients with high-grade astrocytic tumors (19 AA and 32 GBM).
  • The relation of geminin expression to clinical outcome in these malignant brain tumors was analyzed by using the Kaplan-Meier method and a Cox proportional hazards regression model.
  • Similarly, the Cox regression analysis showed that geminin expression has a significant correlation with survival in patients with high-grade astrocytoma (P = .0278), especially in an early stage.
  • CONCLUSIONS: Although it is an inhibitor of DNA proliferation and, thus, is a cell cycle inhibitor, geminin expression was found in all malignant astrocytic tumors.
  • The geminin LI was a significant predictive factor of outcomes in patients with high-grade astrocytoma, with higher expression indicating a good prognosis.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Cell Cycle Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17262828.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / GMNN protein, human; 0 / Geminin
  •  go-up   go-down


13. Richter S, Schoch B, Kaiser O, Groetschel H, Dimitrova A, Hein-Kropp C, Maschke M, Gizewski ER, Timmann D: Behavioral and affective changes in children and adolescents with chronic cerebellar lesions. Neurosci Lett; 2005 Jun 10-17;381(1-2):102-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study was to investigate if clinically relevant affective or behavioral changes as described in adults in the cerebellar affective syndrome by Schmahmann and Sherman [The cerebellar cognitive affective syndrome, Brain 121 (1998) 561-579] are likely to occur as a long-term sequelae of cerebellar vermis lesions in children.
  • Affect and behavior were assessed in children after cerebellar tumor surgery by means of experimenter ratings based on the description of the cerebellar affective syndrome and free ratings by the patients and their parents.
  • Twelve children and adolescents with a former cerebellar astrocytoma surgery without subsequent radiation or chemotherapy participated.
  • [MeSH-major] Cerebellar Diseases / complications. Cerebellar Diseases / diagnosis. Mental Disorders / diagnosis. Mental Disorders / etiology. Mood Disorders / diagnosis. Mood Disorders / etiology


14. Signorelli F, Ruggeri F, Iofrida G, Isnard J, Chirchiglia D, Lavano A, Volpentesta G, Signorelli CD, Guyotat J: Indications and limits of intraoperative cortico-subcortical mapping in brain tumor surgery: an analysis of 101 consecutive cases. J Neurosurg Sci; 2007 Sep;51(3):113-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indications and limits of intraoperative cortico-subcortical mapping in brain tumor surgery: an analysis of 101 consecutive cases.
  • AIM: Here we report our recent experience in supratentorial cortico-subcortical stimulation mapping during surgery for cerebral lesions closely related to sensorimotor and language areas.
  • RESULTS: A macroscopically complete removal of the tumor was carried out in 22 cases out of 28 of group A and in 57 out of 73 of group B.
  • Eighteen patients died for tumor progression, with a mean survival time of 18.7 months.
  • [MeSH-major] Astrocytoma / surgery. Brain Mapping / methods. Brain Neoplasms / surgery. Electric Stimulation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17641576.001).
  • [ISSN] 0390-5616
  • [Journal-full-title] Journal of neurosurgical sciences
  • [ISO-abbreviation] J Neurosurg Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


15. Barhoumi R, Burghardt RC, Qian Y, Tiffany-Castiglioni E: Effects of propofol on intracellular Ca2+ homeostasis in human astrocytoma cells. Brain Res; 2007 May 11;1145:11-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of propofol on intracellular Ca2+ homeostasis in human astrocytoma cells.
  • The effects of propofol, a short-acting general anesthetic, upon cell growth and Ca(2+) signaling in a human astrocytic cell line were examined.
  • [MeSH-major] Astrocytes / drug effects. Brain / drug effects. Calcium / metabolism. Calcium Signaling / drug effects. Propofol / pharmacology
  • [MeSH-minor] Anesthetics, Intravenous / pharmacology. Calcium Channel Agonists / pharmacology. Calcium Channel Blockers / pharmacology. Calcium Channels / drug effects. Calcium Channels / metabolism. Cell Death / drug effects. Cell Death / physiology. Cell Line, Tumor. Cytosol / drug effects. Cytosol / metabolism. Dose-Response Relationship, Drug. Homeostasis / drug effects. Homeostasis / physiology. Humans. Intracellular Fluid / drug effects. Intracellular Fluid / metabolism. Mitochondria / drug effects. Mitochondria / metabolism. Potassium Channels / drug effects. Potassium Channels / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROPOFOL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17328872.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P30-ES09106
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anesthetics, Intravenous; 0 / Calcium Channel Agonists; 0 / Calcium Channel Blockers; 0 / Calcium Channels; 0 / Potassium Channels; 0 / mitochondrial K(ATP) channel; SY7Q814VUP / Calcium; YI7VU623SF / Propofol
  •  go-up   go-down


16. Hatakenaka M, Yoshiura T, Shioyama Y, Honda H: [Future of diagnostic radiology: prediction of treatment outcome using MRI]. Fukuoka Igaku Zasshi; 2010 Mar;101(3):41-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Diffusion Magnetic Resonance Imaging. Glioblastoma / diagnosis. Head and Neck Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20653196.001).
  • [ISSN] 0016-254X
  • [Journal-full-title] Fukuoka igaku zasshi = Hukuoka acta medica
  • [ISO-abbreviation] Fukuoka Igaku Zasshi
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 22
  •  go-up   go-down


17. Nakamura M, Shimada K, Ishida E, Higuchi T, Nakase H, Sakaki T, Konishi N: Molecular pathogenesis of pediatric astrocytic tumors. Neuro Oncol; 2007 Apr;9(2):113-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathogenesis of pediatric astrocytic tumors.
  • Astrocytomas are the most common pediatric brain tumors, accounting for 7%-8% of all childhood cancers.
  • Relatively few studies have been performed on their molecular properties; therefore, classification of pediatric astrocytic tumors into genetic subtypes similar to that of adult tumors remains to be defined.
  • EGFR amplification was detected in only one anaplastic astrocytoma and two glioblastomas, but no amplification was observed for the PDGFR-alpha gene.
  • Loss of heterozygosity (LOH) on 1p/19q and 10p/10q was less common in pediatric astrocytic tumors than in those seen in adults, but the frequency of LOH on 22q was comparable, occurring in 44% of diffuse astrocytomas, 40% of anaplastic astrocytomas, and 61% of glioblastomas.
  • Interestingly, a higher frequency of p53 mutations and LOH on 19q and 22q in tumors from children six or more years of age at diagnosis was found, compared with those from younger children.
  • Our results suggest some differences in children compared to adults in the genetic pathways leading to the formation of de novo astrocytic tumors.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Nov;30(11):1284-90 [10571506.001]
  • [Cites] Acta Neuropathol. 2005 Oct;110(4):402-10 [16155764.001]
  • [Cites] Lab Invest. 2000 Jan;80(1):65-72 [10653004.001]
  • [Cites] Brain Pathol. 2000 Apr;10(2):249-59 [10764044.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jun;59(6):539-43 [10850866.001]
  • [Cites] Lab Invest. 2001 Jan;81(1):77-82 [11204276.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2124-8 [11280776.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1253-62 [11290543.001]
  • [Cites] Brain Pathol. 2001 Apr;11(2):159-68 [11303791.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1715-9 [11577014.001]
  • [Cites] Childs Nerv Syst. 2001 Sep;17(9):503-11 [11585322.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Nov;60(11):1099-104 [11706939.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3155-64 [11753995.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Acta Neuropathol. 2002 Mar;103(3):267-75 [11907807.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):529-36 [12057098.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):117-22 [12241104.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):737-41 [12591717.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):131-6 [15193025.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Cancer Res. 1990 May 15;50(10):2987-90 [2334901.001]
  • [Cites] Cancer. 1993 May 15;71(10 Suppl):3229-36 [8490859.001]
  • [Cites] Brain Pathol. 1993 Jan;3(1):19-26 [8269081.001]
  • [Cites] Oncogene. 1994 Mar;9(3):949-54 [8108140.001]
  • [Cites] Neurosurgery. 1994 Feb;34(2):213-9; discussion 219-20 [8177380.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):427-36 [8057151.001]
  • [Cites] Neurosurgery. 1994 Jun;34(6):967-72; discussion 972-3 [8084407.001]
  • [Cites] Brain Pathol. 1996 Jul;6(3):217-23; discussion 23-4 [8864278.001]
  • [Cites] Neurosurgery. 1996 Feb;38(2):258-64 [8869052.001]
  • [Cites] Cytogenet Cell Genet. 1996;72(2-3):100-12 [8978759.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):304-9 [9000573.001]
  • [Cites] Brain Pathol. 1997 Apr;7(2):755-64 [9161727.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Jul;56(7):782-9 [9210874.001]
  • [Cites] Nat Genet. 1997 Sep;17(1):32-9 [9288095.001]
  • [Cites] Genes Chromosomes Cancer. 1998 May;22(1):9-15 [9591629.001]
  • [Cites] Acta Neuropathol. 1998 Jun;95(6):559-64 [9650746.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Jul;57(7):684-9 [9690672.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1786-92 [10430083.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] Lab Invest. 2005 Feb;85(2):165-75 [15592495.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4085-90 [10632344.001]
  • (PMID = 17327574.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC1871665
  •  go-up   go-down


18. Muratori C, Mangino G, Affabris E, Federico M: Astrocytes contacting HIV-1-infected macrophages increase the release of CCL2 in response to the HIV-1-dependent enhancement of membrane-associated TNFα in macrophages. Glia; 2010 Dec;58(16):1893-904
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Once penetrated the blood-brain barrier (BBB), macrophages closely interact with astrocytes, beginning with those lying beneath the BBB endothelium.
  • In addition, it was a consequence of the HIV-1-induced enhancement of membrane-associated tumor necrosis factor-α in macrophagic cells, and correlated with increased levels of nuclear factor kappaB activation in astroglial cells.
  • [MeSH-major] Astrocytes / virology. Chemokine CCL2 / immunology. HIV Infections / immunology. HIV-1. Macrophages / virology. Tumor Necrosis Factor-alpha / immunology
  • [MeSH-minor] Astrocytoma. Brain Neoplasms. Cell Communication / immunology. Chemotaxis / immunology. Coculture Techniques. Gene Expression / immunology. Humans. I-kappa B Proteins / metabolism. Membrane Proteins / immunology. Membrane Proteins / metabolism. Oligonucleotide Array Sequence Analysis. U937 Cells

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20737475.001).
  • [ISSN] 1098-1136
  • [Journal-full-title] Glia
  • [ISO-abbreviation] Glia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCL2 protein, human; 0 / Chemokine CCL2; 0 / I-kappa B Proteins; 0 / Membrane Proteins; 0 / Tumor Necrosis Factor-alpha; 139874-52-5 / NF-kappaB inhibitor alpha
  •  go-up   go-down


19. Sonabend AM, Ulasov IV, Lesniak MS: Emerging role of new transgenic mouse models in glioma research. Expert Rev Anticancer Ther; 2007 Dec;7(12 Suppl):S7-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Disease Models, Animal. Glioma / genetics

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076321.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 66
  •  go-up   go-down


20. Becher OJ, Peterson KM, Khatua S, Santi MR, MacDonald TJ: IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK. J Child Neurol; 2008 Oct;23(10):1205-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK.
  • To identify targets critical to malignant childhood astrocytoma, we compared the expression of receptor tyrosine kinase- associated genes between low-grade and high-grade pediatric astrocytomas.
  • The highest differentially overexpressed gene in high-grade astrocytoma is insulin-like growth factor- binding protein-2 (P = .0006).
  • Insulin-like growth factor- binding protein-2 stimulation had no effect on astrocytoma cell growth and migration, and minimally inhibited insulin-like growth factor-1-mediated migration, but not insulin-like growth factor-2-mediated migration.
  • These findings suggest insulin-like growth factor-binding protein-2 plays a role in astrocytoma progression by promoting DNA-damage repair and therapeutic resistance.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Pathol. 2000 Apr;10(2):249-59 [10764044.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4315-21 [12907597.001]
  • [Cites] Endocrinology. 2001 Apr;142(4):1652-8 [11250947.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):109-19 [11550306.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):143-52 [11544480.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7404-7 [11606370.001]
  • [Cites] Oncogene. 2001 Nov 8;20(51):7542-50 [11709726.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8601-10 [11751371.001]
  • [Cites] Mol Cells. 2002 Apr 30;13(2):159-66 [12018836.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4369-75 [12154042.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4209-16 [12377964.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1587-95 [12414507.001]
  • [Cites] J Biol Chem. 2002 Nov 15;277(46):43830-5 [12235151.001]
  • [Cites] Gene Expr. 2003;11(1):35-45 [12691524.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1865-70 [12702575.001]
  • [Cites] FASEB J. 2003 Oct;17(13):1919-21 [14519668.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5850-8 [14522909.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39882-91 [12881526.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):42886-92 [12917428.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6613-25 [14583454.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6962-70 [14583498.001]
  • [Cites] Nucleic Acids Res. 2003 Dec 15;31(24):7227-37 [14654698.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):873-82 [14661061.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):977-84 [14871828.001]
  • [Cites] Int J Cancer. 1992 Jan 21;50(2):215-22 [1370435.001]
  • [Cites] J Neurosci. 1992 Dec;12(12):4737-44 [1281494.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10553-7 [7504269.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Aug;79(2):428-34 [7519190.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):427-36 [8057151.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):395-405 [8001010.001]
  • [Cites] J Neurosurg. 1997 May;86(5):747-54 [9126887.001]
  • [Cites] Semin Surg Oncol. 1998 Jan-Feb;14(1):3-12 [9407626.001]
  • [Cites] Oncology (Williston Park). 1998 Feb;12(2):233-40; discussion 240, 246 [9507524.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):52-9 [9647172.001]
  • [Cites] Clin Exp Metastasis. 1998 Nov;16(8):729-41 [10211986.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1786-92 [10430083.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4228-32 [10485462.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4368-75 [15899829.001]
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):31182-9 [16000298.001]
  • [Cites] Int J Cancer. 2005 Nov 20;117(4):531-7 [15929110.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):485-94 [16212813.001]
  • [Cites] Virchows Arch. 2003 Apr;442(4):329-35 [12684767.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1391-9; discussion 1399 [12762884.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1425-34; discussion 1434-5 [12762887.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3B):2315-20 [12894509.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6617-22 [11118044.001]
  • (PMID = 18952587.001).
  • [ISSN] 1708-8283
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K08 CA092056; United States / NINDS NIH HHS / NS / R13 NS040925; United States / NINDS NIH HHS / NS / 5R13NS040925-09; United States / NCI NIH HHS / CA / K08 CA92056-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Nuclear Proteins; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.11.1 / DNA-Activated Protein Kinase; EC 2.7.11.1 / PRKDC protein, human
  • [Other-IDs] NLM/ NIHMS473094; NLM/ PMC3674842
  •  go-up   go-down


21. Choudry Q, Patel HC, Gurusinghe NT, Evans DG: Radiation-induced brain tumours in nevoid basal cell carcinoma syndrome: implications for treatment and surveillance. Childs Nerv Syst; 2007 Jan;23(1):133-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced brain tumours in nevoid basal cell carcinoma syndrome: implications for treatment and surveillance.
  • INTRODUCTION: We report two cases of radiation-induced intracranial tumours after treatment for medulloblastoma presenting in children with nevoid basal cell carcinoma syndrome.
  • This is particularly important as the initial tumour in this cohort is of the 'less aggressive' desmoplastic subtype.
  • [MeSH-major] Astrocytoma / etiology. Brain Neoplasms / etiology. Cerebellar Neoplasms / radiotherapy. Medulloblastoma / radiotherapy. Neoplasms, Radiation-Induced. Radiotherapy / adverse effects

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1991 Nov;64(5):959-61 [1931625.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):832-45 [10071274.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):618-24 [12879481.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):399-408 [15231246.001]
  • [Cites] Br J Cancer. 1997;76(2):141-5 [9231911.001]
  • [Cites] J Neurosurg. 1997 Feb;86(2):286-8 [9010431.001]
  • [Cites] J Neurosurg. 1999 Dec;91(6):971-7 [10584843.001]
  • [Cites] Br J Neurosurg. 1991;5(6):643-6 [1772613.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):269-79 [10661332.001]
  • [Cites] Lancet Oncol. 2004 Apr;5(4):209-18 [15050952.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Jun-Jul;23(5):268-71 [11464980.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Oct;23(7):431-6 [11878577.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):984-93 [14970185.001]
  • (PMID = 16977487.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Rozen WM, Joseph S, Lo PA: Spontaneous regression of low-grade gliomas in pediatric patients without neurofibromatosis. Pediatr Neurosurg; 2008;44(4):324-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the first documented case of spontaneous regression of a temporal lobe pilocytic astrocytoma in a patient without neurofibromatosis.
  • As such, spontaneous tumor regression is an important outcome to be considered for pediatric low-grade gliomas and pilocytic astrocytomas.
  • [MeSH-major] Astrocytoma. Brain Neoplasms. Neoplasm Regression, Spontaneous. Temporal Lobe

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel
  • (PMID = 18504420.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 26
  •  go-up   go-down


23. Wacker A, Will BE, Schöning M, Neunhoeffer F: [Intracerebral bleeding as the first symptom of a congenital anaplastic astrocytoma]. Z Geburtshilfe Neonatol; 2008 Oct;212(5):194-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracerebral bleeding as the first symptom of a congenital anaplastic astrocytoma].
  • An ultrasound scan of the brain showed an intracerebral bleeding.
  • A CT scan showed cerebral bleeding in the left parieto-occipital region, partially clotted, with a space-demanding effect.
  • No tumour was found, but an anaplastic astrocytoma (WHO Grade III) was diagnosed histologically.
  • Serial ultrasound investigations of the brain showed a normal midline and a redevelopment of the left-sided ventricle.
  • After surgery no tumour was visible in the MRI.
  • Six weeks later, a tumour was found in the area of the initial bleeding region on MRI.
  • In the literature, survival rates of 36-50 % were found after complete tumour resection.
  • In cases of neonatal intracerebral bleeding, a tumour might be the cause of the haemorrhage.
  • [MeSH-major] Astrocytoma / congenital. Brain Neoplasms / congenital. Cerebral Hemorrhage / congenital
  • [MeSH-minor] Diagnosis, Differential. Echoencephalography. Fatal Outcome. Female. Humans. Infant, Newborn. Magnetic Resonance Imaging. Occipital Lobe / pathology. Temporal Lobe / pathology. Tomography, X-Ray Computed. Trephining

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18956278.001).
  • [ISSN] 0948-2393
  • [Journal-full-title] Zeitschrift für Geburtshilfe und Neonatologie
  • [ISO-abbreviation] Z Geburtshilfe Neonatol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Xiangsong Z, Weian C: Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET. J Neurooncol; 2007 May;82(3):305-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET.
  • Differentiation of posttherapy radiation necrosis from recurrent brain tumor remains a challenging diagnostic problem.
  • The present study assessed the role of (13)N-NH(3) PET in differentiating recurrent cerebral astrocytoma from radiation necrosis.
  • METHODS: Seven patients, who were previously treated with conventional external-beam radiation therapy after surgical resection for cerebral astrocytomas, and showed the enhancing brain lesions on T1-weighted gadiolinium-enhanced MR studies performed in 6 months or above after the radiotherapies, were examined prospectively with (13)N-NH(3) and FDG PET.
  • Five lesions with tumor recurrence and two with radiation necrosis were histologically verified by either surgical resection or stereotactic biopsy.
  • RESULTS: In all eight lesions the (13)N-NH(3) PET scans were concordant with the final diagnosis (100%, 8/8).
  • The lesions with recurrent tumor showed moderately to markedly increased (13)N-NH(3) uptake (grade = 4-5).
  • The FDG PET scans were concordant with the final diagnosis in six of eight lesions (75%, 6/8), and there were one false-negative result and one false-positive result.
  • The other lesion with anaplastic astrocytoma showed moderately increased (13)N-NH(3) uptake (grade = 4), but slightly less FDG uptake than surrounding area (grade = 2).
  • CONCLUSIONS: The recurrent astrocytomas showed increased (13)N-NH(3) uptake, and the radiation necrosis showed absent or less (13)N-NH(3) uptake, and (13)N-NH(3) seem superior to (18)F-FDG for this purpose, suggesting that (13)N-NH(3) is a promising tracer for separating radiation necrosis from astrocytoma recurrence.
  • [MeSH-major] Astrocytoma / pathology. Brain Diseases / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / diagnosis. Nitrogen Radioisotopes
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Necrosis / etiology. Necrosis / pathology. Pilot Projects. Positron-Emission Tomography. Radiopharmaceuticals. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroradiology. 2000 Feb;42(2):149-52 [10663496.001]
  • [Cites] Ann Neurol. 1993 May;33(5):540-8 [8498831.001]
  • [Cites] Neuropathol Appl Neurobiol. 1982 May-Jun;8(3):227-36 [6126838.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Mar;80(6):1521-5 [6572914.001]
  • [Cites] J Nucl Med. 2000 Nov;41(11):1861-7 [11079496.001]
  • [Cites] J Biol Chem. 1979 Jun 25;254(12):4982-92 [36379.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Nov-Dec;12 (6):1187-92 [1763749.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 Mar;19(3):407-13 [9541290.001]
  • [Cites] J Neurooncol. 1991 Feb;10 (1):85-91 [2022975.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 May;21(5):901-9 [10815666.001]
  • [Cites] Br J Radiol. 1982 Nov;55(659):797-804 [6982741.001]
  • [Cites] No To Shinkei. 1993 Apr;45(4):362-8 [8101449.001]
  • [Cites] Stroke. 1981 Sep-Oct;12(5):607-19 [7303045.001]
  • [Cites] J Neurosurg. 1992 Oct;77(4):565-70 [1527616.001]
  • [Cites] J Nucl Med. 2004 Nov;45(11):1931-8 [15534065.001]
  • [Cites] J Neurooncol. 2006 Jun;78(2):145-51 [16739028.001]
  • [Cites] Neuropathol Appl Neurobiol. 1990 Jun;16(3):205-11 [1976235.001]
  • (PMID = 17120157.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nitrogen Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


25. Wang Y, Xiang J, Fang J: [Mutation analysis of neural cell adhesion molecules in human astrocytoma]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jun;34(6):510-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mutation analysis of neural cell adhesion molecules in human astrocytoma].
  • RESULTS: An A-C transversion was found at position 1 126 in NCAM's 7 exon in a patient with glioblastoma from 43 astrocytoma.
  • CONCLUSION: Structural change in the protein caused by point mutation may be the reason for tumorigenesis of astrocytoma.
  • [MeSH-major] Antigens, CD56 / genetics. Astrocytoma / genetics. Brain Neoplasms / genetics. Point Mutation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19587433.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / NCAM1 protein, human
  •  go-up   go-down


26. National Toxicology Program: Toxicology and carcinogenesis studies of divinylbenzene-HP (Cas No. 1321-74-0) in F344/N rats and B6C3F1 mice (inhalation studies). Natl Toxicol Program Tech Rep Ser; 2006 Nov;(534):1-290
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Divinylbenzene-HP was nominated for study by the National Cancer Institute because of the potential for worker exposure and the structural similarity of divinylbenzene to styrene, a potential human carcinogen.
  • The incidences of malignant glial cell tumors (malignant astrocytoma and oligodendroglioma) in the brain were slightly increased in 100 and 200 ppm males, and the incidence in the 200 ppm group exceeded the historical range for chamber controls.
  • CONCLUSIONS: Under the conditions of this 2-year inhalation study, there was equivocal evidence of carcinogenic activity of divinylbenzene-HP in male F344/N rats based upon the occurrence of carcinomas in the kidney and glial tumors in the brain.

  • Hazardous Substances Data Bank. VINYLSTYRENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17342197.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vinyl Compounds; IZ715T4SBU / divinyl benzene
  •  go-up   go-down


27. Nakagawa Y, Kageji T, Mizobuchi Y, Kumada H, Nakagawa Y: Clinical results of BNCT for malignant brain tumors in children. Appl Radiat Isot; 2009 Jul;67(7-8 Suppl):S27-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical results of BNCT for malignant brain tumors in children.
  • It is very difficult to treat the patients with malignant brain tumor in children, especially under 3 years, because the conventional irradiation cannot be applied due to the damage of normal brain tissue.
  • However, boron neutron capture therapy (BNCT) has tumor selectivity such that it can make damage only in tumor cells.
  • We evaluated the clinical results and courses in patients with malignant glioma under 15 years.
  • Among 183 patients with brain tumors treated by our group using BSH-based intra-operative BNCT, 23 patients were under 15 years.
  • All GBM and PNET patients died due to CSF and/or CNS dissemination without local tumor regrowth.
  • All pontine glioma patients died due to regrowth of the tumor.
  • Four of 6 anaplastic astrocytoma and 1 anaplastic ependymoma patients alive without tumor recurrence.
  • BNCT can be applied to malignant brain tumors in children, especially under 3 years instead of conventional radiation.
  • [MeSH-major] Boron Neutron Capture Therapy. Brain Neoplasms / radiotherapy. Glioma / radiotherapy
  • [MeSH-minor] Adolescent. Astrocytoma / pathology. Astrocytoma / radiotherapy. Child. Child, Preschool. Ependymoma / pathology. Ependymoma / radiotherapy. Fatal Outcome. Female. Glioblastoma / pathology. Glioblastoma / radiotherapy. Humans. Infant. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness / pathology. Neuroectodermal Tumors, Primitive / pathology. Neuroectodermal Tumors, Primitive / radiotherapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19406652.001).
  • [ISSN] 1872-9800
  • [Journal-full-title] Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
  • [ISO-abbreviation] Appl Radiat Isot
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


28. Arismendi-Morillo G, Castellano A: Tumoral micro-blood vessels and vascular microenvironment in human astrocytic tumors. A transmission electron microscopy study. J Neurooncol; 2005 Jul;73(3):211-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumoral micro-blood vessels and vascular microenvironment in human astrocytic tumors. A transmission electron microscopy study.
  • The development of peritumoral edema is thought to be due to extravasation of plasma water and macromolecules through a defective blood-brain barrier (BBB), but the exact mechanism by which occurs is poorly understood.
  • The aim of this study was analyze at submicroscopic level the morphological changes in both micro-blood vessels and vascular microenvironment of astrocytic tumors in an attempt of understanding the pathological aspects that may help in the future researches for the design of future therapeutic strategies.
  • Biopsies of 25 patients with pathological diagnosis of astrocytic tumors were examined with the transmission electron microscope.
  • Both open and close tight junctions were observed in the micro-blood vessels, inclusive in a same tumor.
  • Pericytes exhibited edema and phagocytoced material, astrocytic perivascular-feet showed signs of oncosis and necrosis, co-option vessels totally surrounding by neoplastic cells also were seen.
  • The ultrastructural abnormalities observed in both junctional complexes and vascular microenvironment suggest a multi-factorial pathobiology process, probably hypoxia intratumoral, calcium overload in endothelial cells, and degradative effects of metalloproteinases over the basal membrane appear as determinant factors that leading to structural modifications of junctional complexes, therefore, treatment with both HIF-1alpha and metalloproteinases inhibitors possibly can contribute with the pharmacological handling of the peritumoral edema associated with astrocytic tumors.
  • [MeSH-major] Astrocytoma / blood supply. Brain Neoplasms / blood supply. Capillaries / pathology. Capillaries / ultrastructure. Tight Junctions / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] No Shinkei Geka. 1988;16(5 Suppl):563-8 [3399012.001]
  • [Cites] Am J Physiol. 1998 May;274(5 Pt 2):R1203-11 [9644031.001]
  • [Cites] Am J Pathol. 1991 Jun;138(6):1335-47 [1711288.001]
  • [Cites] Acta Neuropathol. 2000 Sep;100(3):323-31 [10965803.001]
  • [Cites] Prog Neurobiol. 2002 Dec;68(5):311-23 [12531232.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 May;54(3):304-10 [7745429.001]
  • [Cites] Trends Neurosci. 1990 May;13(5):174-8 [1693235.001]
  • [Cites] Eur J Cell Biol. 2000 Oct;79(10):707-17 [11089919.001]
  • [Cites] Stroke. 2002 Jun;33(6):1706-11 [12053015.001]
  • [Cites] Neuropathol Appl Neurobiol. 1999 Apr;25(2):104-12 [10215998.001]
  • [Cites] No Shinkei Geka. 1989 Nov;17(11):999-1004 [2594159.001]
  • [Cites] J Neurosci Res. 1998 Sep 15;53(6):637-44 [9753191.001]
  • [Cites] J Neurooncol. 1987;5(4):299-307 [2831312.001]
  • [Cites] J Neurosurg. 2001 Mar;94(3):464-73 [11235952.001]
  • [Cites] Neuropathol Appl Neurobiol. 2001 Oct;27(5):384-95 [11679090.001]
  • [Cites] Pharmacol Rev. 1997 Jun;49(2):143-55 [9228664.001]
  • [Cites] J Neurosurg. 2001 Dec;95(6):1012-9 [11765816.001]
  • [Cites] Brain Res Brain Res Rev. 2001 Oct;36(2-3):258-64 [11690623.001]
  • [Cites] Neuroreport. 2000 Apr 7;11(5):1081-4 [10790886.001]
  • [Cites] J Neurooncol. 2000 Oct-Nov;50(1-2):99-108 [11245285.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5A):3287-92 [11062755.001]
  • [Cites] Brain Tumor Pathol. 2000;17(1):1-6 [10982003.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Jun;28(3):210-7 [12060345.001]
  • [Cites] Trends Genet. 1990 Apr;6(4):121-5 [2132731.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):920-7 [14871821.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] Pathol Biol (Paris). 1998 Mar;46(3):176-80 [9769913.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2002 Apr;282(4):H1485-94 [11893586.001]
  • [Cites] J Cell Sci. 1994 May;107 ( Pt 5):1347-57 [7929640.001]
  • [Cites] J Neurosurg. 1970 Feb;32(2):127-44 [5411991.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(7):870-5; discussion 875-6 [8869716.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2001 Jan;280(1):H434-40 [11123261.001]
  • [Cites] Neurosurgery. 1999 Apr;44(4):732-40; discussion 740-1 [10201297.001]
  • [Cites] Pediatr Neurosci. 1989;15(3):105-10 [2702345.001]
  • [Cites] Glia. 2002 Nov;40(2):252-9 [12379912.001]
  • [Cites] J Biol Chem. 1996 Jan 12;271(2):603-6 [8557658.001]
  • [Cites] Acta Neuropathol. 2002 Jul;104(1):85-91 [12070669.001]
  • [Cites] Physiol Rev. 1999 Oct;79(4):1431-568 [10508238.001]
  • [Cites] Cell Tissue Res. 2004 Feb;315(2):157-66 [14615934.001]
  • [Cites] No Shinkei Geka. 1985 Mar;13(3):275-81 [2989720.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] Vascul Pharmacol. 2002 Jun;38(6):323-37 [12529927.001]
  • [Cites] Trends Neurosci. 2001 Dec;24(12):719-25 [11718877.001]
  • [Cites] Acta Neuropathol. 1989;78(6):561-71 [2554636.001]
  • [Cites] J Biol Chem. 1995 Nov 24;270(47):28316-24 [7499331.001]
  • [Cites] J Anat. 2002 Jun;200(6):639-46 [12162731.001]
  • [Cites] Neuroradiology. 1999 Nov;41(11):820-5 [10602854.001]
  • [Cites] Neuroscience. 1998 Oct;86(4):1245-57 [9697130.001]
  • [Cites] Neurosurgery. 1992 Jun;30(6):891-6 [1614593.001]
  • (PMID = 15980971.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Amos S, Mut M, diPierro CG, Carpenter JE, Xiao A, Kohutek ZA, Redpath GT, Zhao Y, Wang J, Shaffrey ME, Hussaini IM: Protein kinase C-alpha-mediated regulation of low-density lipoprotein receptor related protein and urokinase increases astrocytoma invasion. Cancer Res; 2007 Nov 1;67(21):10241-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein kinase C-alpha-mediated regulation of low-density lipoprotein receptor related protein and urokinase increases astrocytoma invasion.
  • Low-density lipoprotein receptor-related protein (LRP) is expressed by glioblastoma, but the role of this receptor in astrocytic tumor invasion remains poorly understood.
  • Pretreatment of tumor cells with PKC inhibitors, phosphoinositide 3-kinase (PI3K) inhibitor, PKC-alpha small interfering RNA (siRNA), and short hairpin RNA abrogated phorbol 12-myristate 13-acetate-induced down-regulation of LRP and inhibited astrocytic tumor invasion in vitro.
  • In xenograft glioblastoma mouse model and in vitro transmembrane invasion assay, LRP-deficient cells, which secreted high levels of urokinase-type plasminogen activator (uPA), invaded extensively the surrounding normal brain tissue, whereas the LRP-overexpressing and uPA-deficient cells did not invade into the surrounding normal brain. siRNA, targeted against uPA in LRP-deficient clones, attenuated their invasive potential.
  • Taken together, our results strongly suggest the involvement of PKC-alpha/PI3K signaling pathways in the regulation of LRP-mediated astrocytoma invasion.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):447-61 [10571407.001]
  • [Cites] Oncogene. 2004 Dec 2;23(56):9062-9 [15489897.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1063-9 [10737390.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2300-3 [10786698.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):22348-54 [10806212.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Sep;279(3):L429-38 [10956616.001]
  • [Cites] Biochem J. 2000 Oct 1;351(Pt 1):95-105 [10998351.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(4):1185-95 [11158305.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):15498-503 [11279011.001]
  • [Cites] J Clin Invest. 2001 Sep;108(6):779-84 [11560943.001]
  • [Cites] Oncologist. 2002;7(1):17-33 [11854544.001]
  • [Cites] Trends Endocrinol Metab. 2002 Mar;13(2):66-74 [11854021.001]
  • [Cites] J Biol Chem. 2002 May 3;277(18):15499-506 [11854294.001]
  • [Cites] J Biol Chem. 2002 Nov 8;277(45):43143-51 [12193592.001]
  • [Cites] Science. 2003 Apr 11;300(5617):329-32 [12690199.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):15056-64 [12586837.001]
  • [Cites] Int J Oncol. 2003 Sep;23(3):641-8 [12888899.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):5967-75 [12955075.001]
  • [Cites] J Cell Sci. 2004 Jan 15;117(Pt 2):131-2 [14676268.001]
  • [Cites] Nature. 1984 Apr 19-25;308(5961):693-8 [6232463.001]
  • [Cites] EMBO J. 1988 Dec 20;7(13):4119-27 [3266596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Aug;86(15):5810-4 [2762297.001]
  • [Cites] EMBO J. 1990 Jun;9(6):1769-76 [2112085.001]
  • [Cites] Neurosurgery. 1991 Sep;29(3):399-403; discussion 403-4 [1656312.001]
  • [Cites] Neurosurgery. 1991 Dec;29(6):880-6; discussion 886-7 [1758601.001]
  • [Cites] J Biol Chem. 1992 Jul 25;267(21):14543-6 [1378833.001]
  • [Cites] Cell Tissue Res. 1992 Sep;269(3):375-82 [1423505.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):217-28 [15674479.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):7729-38 [15618223.001]
  • [Cites] Oncogene. 2006 Jun 1;25(23):3286-95 [16407820.001]
  • [Cites] J Neurosurg. 1993 May;78(5):762-6 [8385709.001]
  • [Cites] J Biol Chem. 1993 Oct 15;268(29):21862-7 [7691818.001]
  • [Cites] FEBS Lett. 1994 Feb 7;338(3):301-5 [8307199.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):5016-20 [8069869.001]
  • [Cites] Ann N Y Acad Sci. 1994 Sep 10;737:273-90 [7524402.001]
  • [Cites] J Biol Chem. 1994 Nov 25;269(47):29874-82 [7961982.001]
  • [Cites] J Biol Chem. 1995 Dec 1;270(48):28495-8 [7499357.001]
  • [Cites] Curr Opin Cell Biol. 1996 Apr;8(2):168-73 [8791416.001]
  • [Cites] Cell Growth Differ. 1996 Nov;7(11):1507-12 [8930400.001]
  • [Cites] Brain Res. 1997 Feb 7;747(2):313-7 [9046007.001]
  • [Cites] Cell Biol Toxicol. 1997 Mar;13(3):141-53 [9088624.001]
  • [Cites] J Biol Chem. 1997 May 30;272(22):14372-9 [9162074.001]
  • [Cites] J Clin Invest. 1998 Feb 1;101(3):689-95 [9449704.001]
  • [Cites] Biochem J. 1998 Dec 1;336 ( Pt 2):381-6 [9820815.001]
  • [Cites] Brain Tumor Pathol. 1998;15(1):23-30 [9879460.001]
  • [Cites] Glia. 1999 Jan;25(1):71-84 [9888299.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3369-73 [10416596.001]
  • [Cites] J Cell Sci. 2000 Jan;113 ( Pt 1):123-34 [10591631.001]
  • (PMID = 17974965.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS035122; United States / NHLBI NIH HHS / HL / P01HL48807; United States / NCI NIH HHS / CA / CA090851; United States / NCI NIH HHS / CA / R01 CA090851; United States / NINDS NIH HHS / NS / R29 NS035122; United States / NINDS NIH HHS / NS / NS035122-10; United States / NINDS NIH HHS / NS / R01 NS035122-10; United States / NINDS NIH HHS / NS / NS035122; United States / NHLBI NIH HHS / HL / P01 HL048807
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Low Density Lipoprotein Receptor-Related Protein-1; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.13 / Protein Kinase C-alpha; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator; NI40JAQ945 / Tetradecanoylphorbol Acetate
  • [Other-IDs] NLM/ NIHMS48323; NLM/ PMC2386949
  •  go-up   go-down


30. Schittenhelm J, Mittelbronn M, Nguyen TD, Meyermann R, Beschorner R: WT1 expression distinguishes astrocytic tumor cells from normal and reactive astrocytes. Brain Pathol; 2008 Jul;18(3):344-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1 expression distinguishes astrocytic tumor cells from normal and reactive astrocytes.
  • Particularly in small brain biopsies, it might be difficult to distinguish reactive astrogliosis from low-grade or infiltration zones of high-grade astrocytomas.
  • Recently, the over-expression of Wilms' tumor gene product WT1 was reported in astrocytic tumor cells.
  • Therefore, we investigated WT1 expression in paraffin-embedded brain sections from 28 controls, 48 cases with astrogliosis of various etiology and 219 astrocytomas [World Health Organization (WHO) grades I-IV] by immunohistochemistry.
  • In astrocytomas, WT1-positive tumor cells were found in pilocytic astrocytomas (66.7% of cases), diffuse astrocytomas (52.7%) WHO grade II (52.7%), anaplastic astrocytomas (83.4%) and glioblastomas (98.1%).
  • Overall, the majority of all astrocytic neoplasms (84.5%) expressed WT1.
  • Establishing a cut-off value of 0% immunoreactive tumor cells served to recognize neoplastic astrocytes with 100% specificity and 68% sensitivity and was associated with positive and negative predictive values of 1 and 0.68, respectively.
  • [MeSH-major] Astrocytes / metabolism. Astrocytoma / metabolism. Brain Neoplasms / metabolism. Gliosis / metabolism. WT1 Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Endothelial Cells / metabolism. Female. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18371184.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / WT1 Proteins
  •  go-up   go-down


31. Iacob G, Dinca EB: Current data and strategy in glioblastoma multiforme. J Med Life; 2009 Oct-Dec;2(4):386-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM) or astrocytoma grade IV on WHO classification is the most aggressive and the most frequent of all primary brain tumors.
  • Glioblastoma is multiforme, resistant to therapeutic interventions illustrating the heterogeneity exhibited by this tumor in its every aspect, including clinical presentation, pathology, genetic signature.
  • [MeSH-major] Brain Neoplasms / surgery. Glioblastoma / surgery
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Chromosome Mapping. Diagnosis, Differential. Gene Amplification. Humans. Middle Aged. Mutation. Oncogenes. PTEN Phosphohydrolase / deficiency. PTEN Phosphohydrolase / genetics. Prognosis. Receptor, Epidermal Growth Factor / genetics. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • [Cites] Nat Clin Pract Neurol. 2007 Sep;3(9):E1 [17805242.001]
  • [Cites] Nat Rev Genet. 2001 Feb;2(2):120-9 [11253051.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):197-203 [12778011.001]
  • [Cites] Hum Gene Ther. 2003 Sep 1;14(13):1247-54 [12952596.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):889-901 [14580340.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):1-8 [14712205.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):296-307 [15057289.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3728-36 [15173079.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):967-75 [15184253.001]
  • [Cites] J Neurosurg. 1976 Apr;44(4):442-8 [176331.001]
  • [Cites] Nature. 1980 Dec 25;288(5792):724-7 [6256643.001]
  • [Cites] Carcinogenesis. 1985 Jun;6(6):883-6 [4006075.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1988;42:187-92 [3189008.001]
  • [Cites] Nucleic Acids Res. 1989 Aug 25;17(16):6581-90 [2780288.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] J Neurosurg. 1991 Jan;74(1):55-9 [1984507.001]
  • [Cites] Genes Chromosomes Cancer. 1991 Sep;3(5):323-31 [1686725.001]
  • [Cites] J Cell Sci. 1995 Jun;108 ( Pt 6):2369-79 [7673356.001]
  • [Cites] In Vivo. 1997 Nov-Dec;11(6):453-61 [9509295.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3675-85 [9851974.001]
  • [Cites] J Neurosurg. 1963 Feb;20:122-36 [14192080.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Cancer Treat Rev. 2005 Apr;31(2):79-89 [15847978.001]
  • [Cites] Curr Neurol Neurosci Rep. 2005 May;5(3):198-206 [15865885.001]
  • [Cites] Neurologist. 2005 Nov;11(6):362-5 [16286879.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):328-31 [16428468.001]
  • [Cites] Ann Intern Med. 2006 Mar 7;144(5):337-43 [16520474.001]
  • [Cites] Nat Med. 2007 Jan;13(1):84-8 [17159987.001]
  • [Cites] Pediatr Neurosurg. 2007;43(3):192-201 [17409788.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Neuro Oncol. 2008 Dec;10(6):1025-34 [18667747.001]
  • [Cites] J Med Life. 2009 Oct-Dec;2(4):386-93 [20108752.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1122-8 [11221842.001]
  • (PMID = 20108752.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 45
  • [Other-IDs] NLM/ PMC3019011
  •  go-up   go-down


32. Custódio AC, Almeida LO, Pinto GR, Santos MJ, Almeida JR, Clara CA, Rey JA, Casartelli C: GSTP1 Ile105Val polymorphism in astrocytomas and glioblastomas. Genet Mol Res; 2010;9(4):2328-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined GSTP1 Ile105Val polymorphism using PCR-RFLP in 80 astrocytoma and glioblastoma samples.
  • Patients who had the Val allele of the GSTP1 Ile105Val polymorphism had an increased risk of tumor development (odds ratio = 8.60; 95% confidence interval = 4.74-17.87; P < 0.001).
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Glioblastoma / genetics. Glutathione Transferase / genetics. Isoleucine / genetics. Polymorphism, Single Nucleotide. Valine / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. L-Valine .
  • Hazardous Substances Data Bank. L-Isoleucine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21128213.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / DNA Primers; 04Y7590D77 / Isoleucine; EC 2.5.1.18 / Glutathione Transferase; HG18B9YRS7 / Valine
  •  go-up   go-down


33. Matsuura M, Oguni H, Funatsuka M, Osawa M, Yamane F, Hori T, Shimizu H: [Clinical study on temporal lobe epilepsy in childhood caused by temporal lobe space-occupying lesions]. No To Hattatsu; 2008 May;40(3):249-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain MRI demonstrated SOLs in the mesiotemporal lobe in 9, and laterotemporal lobe in the remaining 2 patients.
  • [MeSH-major] Astrocytoma / complications. Astrocytoma / diagnosis. Brain Neoplasms / complications. Brain Neoplasms / diagnosis. Diagnostic Imaging. Epilepsy, Temporal Lobe / diagnosis. Temporal Lobe


34. Yao Y, Kubota T, Takeuchi H, Sato K: Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology; 2005 Sep;25(3):201-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody.
  • There are conflicting reports as to whether the degree of angiogenesis as measured by microvessel density (MVD) has a prognostic value in astrocytic tumors.
  • To clarify the validity of anti-CD105 antibody in the evaluation of angiogenesis, we assessed MVD using an anti-CD105 monoclonal antibody (mAb) (CD105-MVD) and an anti-CD31 mAb (CD31-MVD) in a series of 50 astrocytic tumors, and correlated MVD with expression of the key angiogenic factor vascular endothelial growth factor (VEGF) and prognosis.
  • The mean CD31-MVD and CD105-MVD was 36.7 and 24.8 for low-grade astrocytoma (LGA), 48.0 and 42.7 for anaplastic astrocytoma, 55.3 and 51.9 for glioblastoma multiforme (GBM), respectively.
  • Whereas the MST of patients with higher CD31-MVD tumors seemed to be shorter than that of lower CD31-MVD patients within each tumor grade, the differences were not statistically significant.
  • These findings suggest that anti-CD105 mAb may be a better marker than anti-CD31 mAb in evaluation of angiogenesis and prediction of prognosis in astrocytic tumors.
  • [MeSH-major] Antibodies, Monoclonal. Astrocytoma / blood supply. Biomarkers, Tumor / analysis. Brain Neoplasms / mortality. Neovascularization, Pathologic / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16193836.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, CD31; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Receptors, Cell Surface; 0 / Vascular Cell Adhesion Molecule-1; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


35. Machado A, Ribeiro M, Rodrigues M, Ferreira C, Almeida R, Santana I, Castro L, Carpenter S: Primary bilateral thalamic astrocytoma presenting with head tremor, ataxia, and dementia. J Neuropsychiatry Clin Neurosci; 2010;22(3):352e.e7-352.e8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bilateral thalamic astrocytoma presenting with head tremor, ataxia, and dementia.
  • [MeSH-major] Astrocytoma / complications. Ataxia / etiology. Brain Neoplasms / complications. Dementia / etiology. Thalamus / pathology. Tremor / etiology


36. Irwin C, Hunn M, Purdie G, Hamilton D: Delay in radiotherapy shortens survival in patients with high grade glioma. J Neurooncol; 2007 Dec;85(3):339-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A retrospective analysis was performed of 172 patients with a histological diagnosis of WHO Grade 3 or 4 Astrocytoma who had undergone surgery at Wellington Hospital between 1993 and 2003, and who subsequently underwent radiotherapy.
  • Multiple Cox regression analysis showed that age, performance status, tumour grade, extent of surgical resection, radiotherapy dose, and time to radiotherapy from day of surgery were all independently related to survival.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Glioblastoma / radiotherapy. Radiotherapy / methods

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Oncol (R Coll Radiol). 2006 Mar;18(2):93-103 [16523808.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):535-43 [10348282.001]
  • [Cites] Br J Cancer. 1991 Oct;64(4):769-74 [1654987.001]
  • [Cites] Radiother Oncol. 2000 Nov;57(2):131-6 [11054516.001]
  • [Cites] Lancet. 1999 Apr 3;353(9159):1119-26 [10209974.001]
  • [Cites] Anticancer Drugs. 2003 Apr;14(4):305-12 [12679735.001]
  • [Cites] J Neurooncol. 1990 Aug;9(1):47-55 [2213115.001]
  • [Cites] Wien Klin Wochenschr. 2003 Jun 24;115(11):389-97 [12879737.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31 [231022.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 17579810.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Yao Y, Tao R, Wang X, Wang Y, Mao Y, Zhou LF: B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro Oncol; 2009 Dec;11(6):757-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells.
  • B7-H1 is the third member of the B7 family that plays important roles in tumor immune evasion.
  • Recent studies have shown that brain tumor stem-like cells (TSCs) contribute to tumorigenesis and radioresistance.
  • However, the relationship between B7-H1 and the clinical behavior of brain TSCs remains unclear.
  • Immunostaining and flow cytometric analysis indicate that B7-H1 was expressed primarily by Ki67-negative tumor cells.
  • Interestingly, we found that CD133-negative tumor cells also had the capacity to form brain tumors.
  • Our data establish a correlation between the expression of the negative costimulatory molecule B7-H1 and the malignancy grade of human gliomas, suggesting that B7-H1 may be a novel tumor marker and target for therapy, although it is not expressed exclusively on brain TSCs.
  • [MeSH-major] Antigens, CD / metabolism. Astrocytoma / metabolism. Brain Neoplasms / metabolism. Neoplastic Stem Cells / metabolism
  • [MeSH-minor] Animals. Antigens, CD274. Biomarkers, Tumor / metabolism. Blotting, Western. CD8-Positive T-Lymphocytes / metabolism. Cell Proliferation. Enzyme-Linked Immunosorbent Assay. Flow Cytometry. Glycoproteins / metabolism. Humans. Immunoenzyme Techniques. Interferon-gamma / metabolism. Ki-67 Antigen / metabolism. Lymphocytes, Tumor-Infiltrating / metabolism. Lymphocytes, Tumor-Infiltrating / pathology. Mice. Mice, SCID. Peptides / metabolism. Prognosis. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 May 1;67(9):4010-5 [17483311.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2462-9 [12750267.001]
  • [Cites] Eur J Cancer. 2007 Jul;43(10):1502-7 [17524637.001]
  • [Cites] J Mol Med (Berl). 2003 May;81(5):281-7 [12721664.001]
  • [Cites] Leukemia. 2003 Oct;17(10):2049-51 [14513057.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7462-7 [14612546.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1140-5 [14871849.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10691-6 [15249675.001]
  • [Cites] J Immunol. 1984 Oct;133(4):1710-5 [6206131.001]
  • [Cites] Exp Neurol. 1999 Aug;158(2):265-78 [10415135.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Immunol Immunother. 2005 Apr;54(4):307-14 [15599732.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):1089-96 [15705911.001]
  • [Cites] Lab Invest. 2005 Mar;85(3):328-41 [15716863.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Apr;288(4):C805-12 [15601754.001]
  • [Cites] Neuroreport. 2005 Jul 13;16(10):1081-5 [15973152.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):317-27 [16482562.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] Stem Cells Dev. 2006 Dec;15(6):931-41 [17253954.001]
  • [Cites] J Immunother. 2007 Apr;30(3):251-60 [17414316.001]
  • [Cites] Nat Med. 1999 Dec;5(12):1365-9 [10581077.001]
  • [Cites] J Exp Med. 2000 Oct 2;192(7):1027-34 [11015443.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Eur J Immunol. 2002 Mar;32(3):634-43 [11857337.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Nat Med. 2002 Aug;8(8):793-800 [12091876.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7 [12218188.001]
  • [Cites] Neuron. 2002 Dec 19;36(6):1021-34 [12495619.001]
  • [Cites] J Immunol. 2003 Feb 1;170(3):1257-66 [12538684.001]
  • [Cites] J Immunol. 2003 Apr 1;170(7):3637-44 [12646628.001]
  • [Cites] J Neurooncol. 2008 Sep;89(2):121-9 [18478183.001]
  • (PMID = 19264916.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Antigens, CD274; 0 / Biomarkers, Tumor; 0 / CD274 protein, human; 0 / Glycoproteins; 0 / Ki-67 Antigen; 0 / Peptides; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2802396
  •  go-up   go-down


38. Mallur PS, Wisoff JH, Lalwani AK: Steroid responsive fluctuating sensorineural hearing loss due to juvenile pilocytic astrocytoma involving the cerebellopontine angle. Int J Pediatr Otorhinolaryngol; 2008 Apr;72(4):529-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Steroid responsive fluctuating sensorineural hearing loss due to juvenile pilocytic astrocytoma involving the cerebellopontine angle.
  • Tumors of the cerebellopontine angle (CPA) are common and represent up to 10% of all intracranial tumors.
  • We report on a rare case of an intrinsic brainstem neoplasm presenting with steroid responsive fluctuating sensorineural hearing loss in a child.
  • Magnetic resonance imaging with contrast enhancement revealed an intrinsic neoplasm of the middle cerebellar peduncle impinging on the 7th/8th neurovascular bundle within the CPA.
  • The patient underwent gross total resection of the juvenile pilocytic astrocytoma via retrosigmoid craniotomy and remains disease free at 2 years postoperatively.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Astrocytoma / complications. Astrocytoma / pathology. Brain Neoplasms / complications. Brain Neoplasms / pathology. Cerebellopontine Angle / pathology. Hearing Loss, Sensorineural / drug therapy. Hearing Loss, Sensorineural / etiology


39. Gil-Benso R, Lopez-Gines C, Benito R, López-Guerrero JA, Callaghan RC, Pellín A, Roldán P, Cerdá-Nicolas M: Concurrent EGFR amplification and TP-53 mutation in glioblastomas. Clin Neuropathol; 2007 Sep-Oct;26(5):224-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme is the most common and most aggressive of the primary brain tumors.
  • We report the histological and genetic study of two glioblastomas, one case arising de novo and the other case arising 3 years after a previously diagnosed anaplastic astrocytoma, with concurrent EGFR amplification and TP-53 mutation.
  • [MeSH-major] Brain Neoplasms / genetics. Genes, p53. Glioblastoma / genetics. Neoplasms, Second Primary / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Astrocytoma / genetics. Astrocytoma / metabolism. Astrocytoma / pathology. Female. Gene Amplification. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation


40. Neyns B, Chaskis C, Joosens E, Menten J, D'Hondt L, Branle F, Sadones J, Michotte A: A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. Cancer Invest; 2008 Apr-May;26(3):269-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.
  • This multicenter cohort study enrolled 19 patients (15 anaplastic astrocytoma, 4 anaplastic oligoastrocytoma) who received temozolomide (100 mg/m2/day for 21 consecutive days every 28-day cycle) at first recurrence, either until disease progression or 12 cycles.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy


41. Chamberlain MC, Johnston S: Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer; 2009 Apr 15;115(8):1734-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Time to tumor progression ranged from 1 to 18 months (median, 6.75 months).
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Bevacizumab. Chromosomes, Human, Pair 1. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19197992.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Alkylating; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


42. Garcia-Navarrete R, Garcia E, Arrieta O, Sotelo J: Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. J Neurooncol; 2010 May;97(3):347-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant gliomas--glioblastoma multiforme and anaplastic astrocytoma--are among the most fatal forms of cancer in humans.
  • We measured the HGF content of cerebrospinal fluid (CSF) from patients with malignant glioma glioblastoma multiforme (WHO IV; n = 14), anaplastic astrocytoma (WHO III; n = 4), and meningioma (WHO I; n = 9), and from control subjects (n = 25), and found a high concentration of HGF in patients with malignant glioma.
  • However, CSF concentrations from glioblastoma multiforme and anaplastic astrocytoma patients were not statistically significantly different (893 +/- 157 vs. 728 +/- 61, respectively; P > 0.01).
  • Also, the HGF concentration in CSF was a reliable means of explaining the highly variable survival of patients with malignant glioma.
  • CSF concentrations of HGF higher than 500 pg/ml were associated with increased mortality whereas values higher than 850 pg/ml were associated with a brief tumor-free period after surgery (9 +/- 0.6 vs. 6 +/- 0.6 months, respectively, P < 0.001).
  • Our findings support the idea that measurement of HGF in CSF could be a useful tool for monitoring the biological activity of malignant glioma.
  • [MeSH-major] Brain Neoplasms / cerebrospinal fluid. Brain Neoplasms / mortality. Glioblastoma / cerebrospinal fluid. Glioblastoma / mortality. Hepatocyte Growth Factor / cerebrospinal fluid

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):129-38 [15015778.001]
  • [Cites] Cancer Lett. 1998 Feb 27;124(2):149-55 [9500204.001]
  • [Cites] Int J Mol Med. 1999 May;3(5):531-6 [10202187.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2005 Mar 30;85(12):835-8 [15949402.001]
  • [Cites] Neurosurgery. 1999 May;44(5):1077-82; discussion 1082-3 [10232541.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1721-9 [16452232.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3210-8 [12115353.001]
  • [Cites] J Neurooncol. 2006 Nov;80(2):143-9 [16648987.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9355-62 [16230398.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2182-9 [16331629.001]
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):517-30 [10571413.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):583-92 [16106403.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6144-52 [17062691.001]
  • [Cites] Front Biosci. 2004 Sep 01;9:3105-23 [15353341.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7443-8 [11416216.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5391-8 [9393765.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4479-86 [15958633.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 15;91(18):1548-56 [10491431.001]
  • [Cites] Neuro Oncol. 2001 Apr;3(2):82-8 [11296484.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):436-51 [16212809.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):10-8 [9988225.001]
  • [Cites] FASEB J. 2002 Jan;16(1):108-10 [11729097.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4578-85 [14555533.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 24;273(1):287-93 [10873600.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 27;235(3):743-7 [9207232.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Aug 10;249(1):73-7 [9705834.001]
  • [Cites] Mol Cancer Res. 2008 Jan;6(1):139-50 [18234969.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1292-8 [16489086.001]
  • (PMID = 19856144.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


43. Bhat SR, Goodwin TL, Burwinkle TM, Lansdale MF, Dahl GV, Huhn SL, Gibbs IC, Donaldson SS, Rosenblum RK, Varni JW, Fisher PG: Profile of daily life in children with brain tumors: an assessment of health-related quality of life. J Clin Oncol; 2005 Aug 20;23(24):5493-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Profile of daily life in children with brain tumors: an assessment of health-related quality of life.
  • RESULTS: One hundred thirty-four patients (73 male; mean age +/- standard deviation, 11.8 +/- 5.4 years; 55 had low-grade glioma, 32 had medulloblastoma/primitive neuroectodermal tumor/embryonal tumor, 17 had malignant astrocytoma, nine had germ-cell tumor, and 21 had other types of tumors) were assessed, each in less than 20 minutes.
  • [MeSH-major] Brain Neoplasms / physiopathology. Brain Neoplasms / psychology. Quality of Life

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Aug 20;23(24):5424-6 [16110000.001]
  • (PMID = 16110009.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


44. Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D, Pfeifer GP: CpG island hypermethylation in human astrocytomas. Cancer Res; 2010 Apr 1;70(7):2718-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Astrocytomas are common and lethal human brain tumors.
  • We have analyzed the methylation status of over 28,000 CpG islands and 18,000 promoters in normal human brain and in astrocytomas of various grades using the methylated CpG island recovery assay.
  • We identified 6,000 to 7,000 methylated CpG islands in normal human brain.
  • Approximately 5% of the promoter-associated CpG islands in the normal brain are methylated.
  • Promoter CpG island methylation is inversely correlated whereas intragenic methylation is directly correlated with gene expression levels in brain tissue.
  • In astrocytomas, several hundred CpG islands undergo specific hypermethylation relative to normal brain with 428 methylation peaks common to more than 25% of the tumors.
  • Genes involved in brain development and neuronal differentiation, such as BMP4, POU4F3, GDNF, OTX2, NEFM, CNTN4, OTP, SIM1, FYN, EN1, CHAT, GSX2, NKX6-1, PAX6, RAX, and DLX2, were strongly enriched among genes frequently methylated in tumors.
  • Our analysis offers mechanistic insights into brain neoplasia suggesting that methylation of the genes involved in neuronal differentiation, in cooperation with other oncogenic events, may shift the balance from regulated differentiation towards gliomagenesis.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):761-5 [17151667.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):237-42 [17211412.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5527-32 [17369352.001]
  • [Cites] Nat Genet. 2007 Apr;39(4):457-66 [17334365.001]
  • [Cites] PLoS Genet. 2007 Oct;3(10):2023-36 [17967063.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):252-7 [18162535.001]
  • [Cites] Oncogene. 2008 Jan 10;27(3):358-65 [17653095.001]
  • [Cites] PLoS Biol. 2008 Jan;6(1):e22 [18232738.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12979-84 [18753622.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Methods Mol Biol. 2009;507:65-75 [18987807.001]
  • [Cites] Cancer Cell. 2009 Jan 6;15(1):45-56 [19111880.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):671-8 [19139413.001]
  • [Cites] Nat Biotechnol. 2009 Apr;27(4):361-8 [19329998.001]
  • [Cites] Epigenetics. 2009 Feb 16;4(2):107-13 [19276669.001]
  • [Cites] Semin Cancer Biol. 2009 Jun;19(3):181-7 [19429482.001]
  • [Cites] Semin Cancer Biol. 2009 Jun;19(3):188-97 [19429483.001]
  • [Cites] Breast Cancer Res. 2009;11(1):R14 [19250546.001]
  • [Cites] Cancer Cell. 2009 Jun 2;15(6):514-26 [19477430.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Sep;48(9):828-41 [19530241.001]
  • [Cites] Epigenetics. 2009 May 16;4(4):255-64 [19550145.001]
  • [Cites] Clin Cancer Res. 2009 Dec 1;15(23):7124-9 [19934302.001]
  • [Cites] Breast Cancer Res Treat. 2010 Apr;120(2):345-55 [19353266.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Genomics. 2002 Nov;80(5):487-98 [12408966.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):52-9 [12794756.001]
  • [Cites] BMC Cancer. 2004 Sep 14;4:65 [15367334.001]
  • [Cites] Nucleic Acids Res. 1997 Jun 15;25(12):2532-4 [9171110.001]
  • [Cites] Mol Biol Evol. 2005 Nov;22(11):2265-74 [16079250.001]
  • [Cites] Cancer Invest. 2006 Feb;24(1):35-40 [16466990.001]
  • [Cites] Cell. 2006 Apr 21;125(2):301-13 [16630818.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6665-74 [16818640.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7490-501 [16885346.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7939-47 [16912168.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8469-76 [16951158.001]
  • [Cites] Nat Genet. 2006 Dec;38(12):1378-85 [17072317.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):157-8 [17200673.001]
  • (PMID = 20233874.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA084469-10A1; United States / NCI NIH HHS / CA / R01 CA084469; United States / NCI NIH HHS / CA / CA084469; United States / NCI NIH HHS / CA / R01 CA084469-10A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS176198; NLM/ PMC2848870
  •  go-up   go-down


45. Tsugu H, Oshiro S, Yanai F, Komatsu F, Abe H, Fukushima T, Nomura Y, Matsumoto S, Nabeshima K, Takano K, Utsunomiya H: Management of pilomyxoid astrocytomas: our experience. Anticancer Res; 2009 Mar;29(3):919-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pilomyxoid astrocytoma (PMA) shows a higher rate of recurrence and cerebrospinal fluid (CSF) dissemination than does pilocytic astrocytoma (PA).
  • After chemotherapy, four patients showed remarkable tumor regression.
  • Nevertheless, one patient died 22 months after initial diagnosis, due to tumor progression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414328.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


46. Messing-Jünger AM, Riemenschneider MJ, Reifenberger G: A 21-year-old female with a third ventricular tumor. Brain Pathol; 2006 Jan;16(1):87-8, 93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 21-year-old female with a third ventricular tumor.
  • On magnetic resonance imaging of the brain, she demonstrated a small contrast-enhancing mass in the posterior part of the third ventricle.
  • Intraoperatively, the tumor showed a close relationship to the choroid plexus of the third ventricle.
  • Most of these tumors were benign schwannomas, except for 2 cases of malignant peripheral nerve sheath tumors.
  • The tumor of our patient is the first reported schwannoma of the third ventricle.
  • Histologically, intraventricular schwannoma needs to be distinguished from other spindle cell tumors, in particular pilocytic astrocytoma and fibroblastic meningioma.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Neurilemmoma / pathology. Neurilemmoma / surgery
  • [MeSH-minor] Adult. Brain / pathology. Female. Humans. Magnetic Resonance Imaging. Neurosurgical Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612987.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


47. Polin RS, Marko NF, Ammerman MD, Shaffrey ME, Huang W, Anderson FA Jr, Caputy AJ, Laws ER: Functional outcomes and survival in patients with high-grade gliomas in dominant and nondominant hemispheres. J Neurosurg; 2005 Feb;102(2):276-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: The goal of this study was to investigate survival and functional outcomes in patients with high-grade intracranial astrocytomas as a function of the location of the lesion in the dominant or nondominant hemisphere (DH and NDH, respectively), and to suggest management strategies for such patients based on these data.
  • METHODS: Data were collected from the Glioma Outcomes Project database, a longitudinal database of demographic, clinical, and outcome data for patients with high-grade intracranial gliomas.
  • Two cohorts were defined based on the location of the tumor in the right or left cerebral hemisphere.
  • The findings in this study demonstrate that fears of increased postoperative morbidity or mortality in otherwise resectable tumors of the DH are unfounded, and the authors therefore advocate that the surgeon's decision to operate be guided by validated outcome predictors and not biased by tumor lateralization.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Glioblastoma / surgery. Karnofsky Performance Status. Postoperative Complications / diagnosis
  • [MeSH-minor] Actuarial Analysis. Cohort Studies. Craniotomy. Databases as Topic. Dominance, Cerebral / physiology. Female. Humans. Male. Middle Aged. Outcome Assessment (Health Care). Prognosis. Reoperation. Surgery, Computer-Assisted. Survival Rate

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15739555.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


48. Zhang M, Wan C, Ji B, Zhang Z, Zhu H, Tian N, La Y, Huang K, Jiang L, He G, Gao L, Zhao X, Shi Y, Huang G, Feng G, He L: Proteome alteration of U251 human astrocytoma cell after inhibiting retinoic acid synthesis. Mol Cell Biochem; 2009 Mar;323(1-2):185-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteome alteration of U251 human astrocytoma cell after inhibiting retinoic acid synthesis.
  • In the current study, we treated the astrocytoma cells with citral, an inhibitor of Ra synthesis.
  • We analyzed the differences in the protein concentrations between the treated and untreated astrocytoma cells by two-dimensional gel electrophoresis (2-DE), Imagemaster software, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS).
  • [MeSH-major] Astrocytoma / metabolism. Proteome / metabolism. Tretinoin / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor / drug effects. Computational Biology / methods. Electrophoresis, Gel, Two-Dimensional. Humans. Molecular Sequence Data. Monoterpenes / pharmacology. Phosphoglycerate Dehydrogenase / genetics. Phosphoglycerate Dehydrogenase / metabolism. Proteomics / methods. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. CITRAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6649-54 [12011429.001]
  • [Cites] Prog Neurobiol. 1996 Jun;49(3):185-214 [8878303.001]
  • [Cites] J Cell Physiol. 2001 Mar;186(3):437-47 [11169983.001]
  • [Cites] Development. 1997 May;124(10 ):2075-85 [9169853.001]
  • [Cites] Int J Dev Neurosci. 1990;8(3):317-26 [2201170.001]
  • [Cites] FASEB J. 2007 Aug;21(10):2496-509 [17438145.001]
  • [Cites] Nat Neurosci. 2007 May;10 (5):615-22 [17435755.001]
  • [Cites] Prog Neurobiol. 2005 Mar;75(4):275-93 [15882777.001]
  • [Cites] J Neurosci. 2001 Oct 1;21(19):7691-704 [11567059.001]
  • [Cites] Mass Spectrom Rev. 2007 May-Jun;26(3):432-50 [17405153.001]
  • [Cites] J Biol Chem. 2001 Dec 28;276(52):49299-309 [11590174.001]
  • [Cites] Aging Cell. 2006 Jun;5(3):267-74 [16842499.001]
  • [Cites] Int J Dev Biol. 2007;51(5):371-8 [17616926.001]
  • [Cites] Arch Histol Cytol. 2003 May;66(2):109-21 [12846552.001]
  • [Cites] Trends Neurosci. 2007 Aug;30(8):417-24 [17631972.001]
  • [Cites] Genes Dev. 1991 Aug;5(8):1333-44 [1907940.001]
  • [Cites] Ann Neurol. 2006 Oct;60(4):476-80 [17068790.001]
  • [Cites] J Nutr Biochem. 2000 Jan;11(1):2-13 [15539337.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Oct 5;276(3):837-42 [11027556.001]
  • [Cites] Mol Psychiatry. 2004 Jul;9(7):684-97, 643 [15098003.001]
  • [Cites] J Biol Chem. 2004 Jan 30;279(5):3573-7 [14645240.001]
  • [Cites] J Biol Chem. 1998 May 8;273(19):11944-53 [9565623.001]
  • [Cites] DNA Res. 2006 Dec 31;13(6):275-86 [17213182.001]
  • [Cites] Nat Clin Pract Neurol. 2006 Dec;2(12):679-89 [17117171.001]
  • [Cites] J Biol Chem. 2003 Apr 11;278(15):13294-301 [12551919.001]
  • [Cites] Neuroscience. 2002;115(2):475-82 [12421614.001]
  • [Cites] Neuroscience. 2006;139(4):1163-72 [16530976.001]
  • [Cites] Science. 2004 Feb 27;303(5662):1378-81 [14988562.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5922-8 [11085504.001]
  • [Cites] Cell Tissue Res. 2000 Oct;302(1):49-58 [11079715.001]
  • [Cites] Dev Biol. 2004 Dec 15;276(2):313-29 [15581867.001]
  • [Cites] Arch Dis Child. 1996 Jun;74(6):542-5 [8758134.001]
  • [Cites] Eur J Neurosci. 2006 Jul;24(2):329-40 [16836633.001]
  • [Cites] Science. 1998 Feb 6;279(5352):863-7 [9452386.001]
  • [Cites] Mol Cell. 2002 May;9(5):1017-29 [12049738.001]
  • [Cites] EMBO J. 2002 Oct 1;21(19):5088-96 [12356725.001]
  • [Cites] J Neurosci. 2005 Aug 17;25(33):7636-47 [16107650.001]
  • [Cites] Behav Brain Res. 2003 Oct 17;145(1-2):37-49 [14529804.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4746-51 [11296301.001]
  • [Cites] Nat Rev Neurosci. 2002 Nov;3(11):843-53 [12415292.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18614-22 [14985362.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3902-7 [16505366.001]
  • [Cites] Hum Mol Genet. 2004 Jan 1;13(1):117-35 [14645198.001]
  • (PMID = 19089318.001).
  • [ISSN] 1573-4919
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Monoterpenes; 0 / Proteome; 5688UTC01R / Tretinoin; EC 1.1.1.95 / Phosphoglycerate Dehydrogenase; T7EU0O9VPP / citral
  •  go-up   go-down


49. Knisely JP, Linskey ME: Less common indications for stereotactic radiosurgery or fractionated radiotherapy for patients with benign brain tumors. Neurosurg Clin N Am; 2006 Apr;17(2):149-67, vii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Less common indications for stereotactic radiosurgery or fractionated radiotherapy for patients with benign brain tumors.
  • Microsurgical resection remains the mainstay of treatment for truly benign brain tumors that can be safely resected because of the potential for permanent cure with most histologic findings, including most of the histologic findings discussed in this article.
  • Physicians must keep in mind the indolent nature of many of the benign brain tumors and realize that many patients are likely to live out normal life spans if tumor control is achieved.
  • Therefore, it is not sufficient simply to consider local tumor control rates and short-term toxicity risks when choosing between surgery, stereotactic radiosurgery, and fractionated radiotherapy.
  • For benign brain tumors, these decisions may have consequences that last for decades.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Patient Selection
  • [MeSH-minor] Astrocytoma / diagnosis. Astrocytoma / radiotherapy. Astrocytoma / surgery. Chordoma / diagnosis. Chordoma / radiotherapy. Chordoma / surgery. Dose Fractionation. Glomus Tumor / diagnosis. Glomus Tumor / radiotherapy. Glomus Tumor / surgery. Humans. Magnetic Resonance Imaging. Neurocytoma / diagnosis. Neurocytoma / radiotherapy. Neurocytoma / surgery. Paraganglioma / diagnosis. Paraganglioma / radiotherapy. Paraganglioma / surgery. Paraganglioma, Extra-Adrenal / diagnosis. Paraganglioma, Extra-Adrenal / radiotherapy. Paraganglioma, Extra-Adrenal / surgery. Pinealoma / diagnosis. Pinealoma / radiotherapy. Pinealoma / surgery. Radiosurgery / methods. Skull Base Neoplasms / diagnosis. Skull Base Neoplasms / radiotherapy. Skull Base Neoplasms / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793507.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 148
  •  go-up   go-down


50. Khwaja FW, Reed MS, Olson JJ, Schmotzer BJ, Gillespie GY, Guha A, Groves MD, Kesari S, Pohl J, Van Meir EG: Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res; 2007 Feb;6(2):559-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients.
  • In this report, we used two proteomic techniques, two-dimensional gel electrophoresis (2-DE), and cleavable Isotope-Coded Affinity Tag (cICAT) to compare CSF proteomes to identify tumor- and grade-specific biomarkers in patients bearing brain tumors of differing histologies and grades.
  • Retrospective analyses were performed on 60 samples derived from astrocytomas WHO grade II, III, and IV, schwannomas, metastastic brain tumors, inflammatory samples, and non-neoplastic controls.
  • We identified 103 potential tumor-specific markers of which 20 were high-grade astrocytoma-specific.
  • These investigations allowed us to identify a spectrum of signature proteins that could be used to distinguish CSF derived from control patients versus those with low- (AII) or high-grade (AIV) astrocytoma.
  • These candidate biomarkers may also have functional properties that play a critical role in the development and malignant progression of human astrocytomas, thus possibly representing novel therapeutic targets for this highly lethal disease.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 May 15;65(10):4088-96 [15899798.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3614-21 [15908672.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4051-8 [15899794.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2303-13 [15781644.001]
  • [Cites] Acta Neurol Belg. 2004 Dec;104(4):148-53 [15742604.001]
  • [Cites] Lab Invest. 2005 Mar;85(3):328-41 [15716863.001]
  • [Cites] FASEB J. 2005 Jan;19(1):153-4 [15522907.001]
  • [Cites] Eur J Hum Genet. 2005 Jan;13(1):118-20 [15470364.001]
  • [Cites] Nat Biotechnol. 1999 Oct;17(10):994-9 [10504701.001]
  • [Cites] J Exp Med. 1997 Oct 20;186(8):1201-12 [9334359.001]
  • [Cites] Oncogene. 1997 Jan 16;14(2):171-83 [9010219.001]
  • [Cites] J Immunol. 1996 Mar 1;156(5):1714-21 [8596018.001]
  • [Cites] Glia. 1995 Nov;15(3):264-88 [8586463.001]
  • [Cites] Immunol Today. 1992 Dec;13(12):507-12 [1463583.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] J Invest Dermatol. 1991 Mar;96(3):318-22 [2002252.001]
  • [Cites] Am J Pathol. 1991 Feb;138(2):349-58 [1992762.001]
  • [Cites] Eur J Pediatr. 1988 Oct;148(1):3-8 [3058481.001]
  • [Cites] Cancer. 1983 Jul 1;52(1):101-4 [6189578.001]
  • [Cites] Dis Markers. 2005;21(2):81-92 [15920295.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3223, 3225 [16104055.001]
  • [Cites] BMC Genomics. 2005;6:145 [16242023.001]
  • [Cites] J Dermatol Sci. 2005 Dec;40(3):157-68 [16150577.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6331-6 [17085642.001]
  • [Cites] Int J Cancer. 2003 Sep 10;106(4):521-7 [12845647.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):102-11 [10656438.001]
  • [Cites] Adv Exp Med Biol. 2000;477:173-85 [10849745.001]
  • [Cites] Histol Histopathol. 2000 Jul;15(3):971-81 [10963139.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):559-64 [11209055.001]
  • [Cites] Clin J Oncol Nurs. 2000 Jul-Aug;4(4):153-8 [11261094.001]
  • [Cites] Int J Neuropsychopharmacol. 2001 Mar;4(1):93-102 [11343634.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):149-60 [11716067.001]
  • [Cites] Adv Anat Pathol. 2002 Jan;9(1):24-36 [11756757.001]
  • [Cites] Neuron. 2002 Jul 3;35(1):25-38 [12123606.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Sep;61(9):767-77 [12230323.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6270-7 [12414657.001]
  • [Cites] J Proteome Res. 2002 Jan-Feb;1(1):47-54 [12643526.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):267-75 [12671665.001]
  • [Cites] Cancer J. 2003 May-Jun;9(3):214-21 [12952306.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Aug;62(8):855-62 [14503641.001]
  • [Cites] Nature. 2003 Oct 30;425(6961):905 [14586448.001]
  • [Cites] Lab Invest. 2004 Apr;84(4):397-405 [14990981.001]
  • [Cites] Clin Biochem. 2004 Nov;37(11):943-52 [15498520.001]
  • [Cites] J Natl Cancer Inst. 1979 Mar;62(3):485-91 [216840.001]
  • [Cites] Clin Chem. 1980 Aug;26(9):1317-22 [7398046.001]
  • (PMID = 17269713.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR 02878; United States / NCI NIH HHS / CA / R01 CA086335; United States / NCI NIH HHS / CA / R01 CA086335-05; United States / NCRR NIH HHS / RR / M01 RR000039; United States / NCRR NIH HHS / RR / RR 12878; United States / NCRR NIH HHS / RR / M01 RR 00039; United States / NCRR NIH HHS / RR / RR 13948; United States / NCI NIH HHS / CA / CA 86335
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Affinity Labels; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Proteome
  • [Other-IDs] NLM/ NIHMS61862; NLM/ PMC2566942
  •  go-up   go-down


51. Elias MC, Tozer KR, Silber JR, Mikheeva S, Deng M, Morrison RS, Manning TC, Silbergeld DL, Glackin CA, Reh TA, Rostomily RC: TWIST is expressed in human gliomas and promotes invasion. Neoplasia; 2005 Sep;7(9):824-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TWIST, a basic helix-loop-helix (bHLH) transcription factor that regulates mesodermal development, has been shown to promote tumor cell metastasis and to enhance survival in response to cytotoxic stress.
  • Our analysis of rat C6 glioma cell-derived cDNA revealed TWIST expression, suggesting that the gene may play a role in the genesis and physiology of primary brain tumors.
  • To further delineate a possible oncogenic role for TWIST in the central nervous system (CNS), we analyzed TWIST expression in human gliomas and normal brain by using reverse transcription polymerase chain reaction, Northern blot analysis, in situ hybridization, and immunohistochemistry.
  • Levels of TWIST mRNA were associated with the highest grade gliomas, and increased TWIST expression accompanied transition from low grade to high grade in vivo, suggesting a role for TWIST in promoting malignant progression.
  • In accord, elevated TWIST mRNA abundance preceded the spontaneous malignant transformation of cultured mouse astrocytes hemizygous for p53.
  • Overexpression of TWIST protein in a human glioma cell line significantly enhanced tumor cell invasion, a hallmark of high-grade gliomas.
  • These findings support roles for TWIST both in early glial tumorigenesis and subsequent malignant progression.
  • TWIST was also expressed in embryonic and fetal human brain, and in neurons, but not glia, of mature brain, indicating that, in gliomas, TWIST may promote the functions also critical for CNS development or normal neuronal physiology.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 1997 May 1;232(2):295-303 [9168805.001]
  • [Cites] Jpn J Cancer Res. 1997 Jun;88(6):564-77 [9263534.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3526-31 [9270024.001]
  • [Cites] Dev Biol. 1997 Sep 15;189(2):205-14 [9299114.001]
  • [Cites] Mol Cell Biol. 1997 Nov;17(11):6563-73 [9343420.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5391-8 [9393765.001]
  • [Cites] J Cell Biochem. 1999 Dec 15;75(4):566-77 [10572240.001]
  • [Cites] J Cell Physiol. 2000 Jul;184(1):101-9 [10825239.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4277-83 [10945642.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3937-43 [11051241.001]
  • [Cites] Bone. 2000 Nov;27(5):591-602 [11062344.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6656-65 [11071894.001]
  • [Cites] Clin Exp Metastasis. 2000;18(2):139-46 [11235989.001]
  • [Cites] J Neurosci. 2001 May 15;21(10):3360-8 [11331365.001]
  • [Cites] Neurol Med Chir (Tokyo). 2001 Apr;41(4):187-95 [11381677.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):26699-707 [11323435.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):44-51 [11550301.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):1-10 [9420066.001]
  • [Cites] J Cell Biochem. 1999 Feb 1;72(2):167-76 [10022499.001]
  • [Cites] Cell. 1999 Feb 5;96(3):405-13 [10025406.001]
  • [Cites] Cell Growth Differ. 1999 Feb;10(2):73-86 [10074901.001]
  • [Cites] Genes Dev. 1999 Sep 1;13(17):2207-17 [10485844.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):655-62 [15542973.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):625-30 [15607966.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):109-19 [11550306.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):124-37 [11550308.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(21):7416-28 [11585922.001]
  • [Cites] Oncogene. 2001 Sep 20;20(42):6018-25 [11593409.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):177-85 [11716069.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):683-8 [11723374.001]
  • [Cites] FASEB J. 2002 Jan;16(1):108-10 [11729097.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):200-7 [11782378.001]
  • [Cites] Nature. 2002 Jan 24;415(6870):436-42 [11807556.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):109-17 [11995811.001]
  • [Cites] Dev Biol. 2002 Jul 15;247(2):251-70 [12086465.001]
  • [Cites] Int J Dev Biol. 2002;46(4):401-13 [12141426.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):474-82 [14724576.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2004;44:239-67 [14744246.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1926-33 [15143086.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):745-52 [15292940.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Nov;78(11):7205-9 [6458820.001]
  • [Cites] Nucleic Acids Res. 1983 Mar 11;11(5):1475-89 [6828386.001]
  • [Cites] Nucleic Acids Res. 1987 Oct 26;15(20):8125-48 [3313277.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Jul;71(1):199-209 [2164527.001]
  • [Cites] Science. 1991 Feb 15;251(4995):761-6 [1846704.001]
  • [Cites] Dev Biol. 1991 Feb;143(2):363-73 [1840517.001]
  • [Cites] J Biol Chem. 1994 Apr 22;269(16):12099-105 [8163514.001]
  • [Cites] Genes Dev. 1995 Mar 15;9(6):686-99 [7729687.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2746-51 [7796398.001]
  • [Cites] Mol Cell Biol. 1995 Aug;15(8):4249-59 [7623819.001]
  • [Cites] Dev Biol. 1995 Nov;172(1):280-92 [7589808.001]
  • [Cites] Mol Cell Biol. 1996 Feb;16(2):626-33 [8552091.001]
  • [Cites] Science. 1996 Jun 7;272(5267):1476-80 [8633239.001]
  • [Cites] Gene. 1997 Mar 10;187(1):83-92 [9073070.001]
  • [Cites] Mol Carcinog. 1997 Mar;18(3):171-6 [9115587.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):616-26 [12154354.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1353-6 [12168810.001]
  • [Cites] Mech Dev. 2002 Jun;114(1-2):51-9 [12175489.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1881-91 [12414534.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8300-8 [12501251.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):203-16 [12612655.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1906-13 [12702582.001]
  • [Cites] Cell Death Differ. 2003 Jun;10(6):641-51 [12761573.001]
  • [Cites] Cancer J. 2003 Mar-Apr;9(2):72-81 [12784872.001]
  • [Cites] J Cell Sci. 2003 Nov 1;116(Pt 21):4409-17 [13130092.001]
  • (PMID = 16229805.001).
  • [ISSN] 1522-8002
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / K08 NS002217; United States / NINDS NIH HHS / NS / KO8 NS02217; United States / NINDS NIH HHS / NS / T32-NS00714424; United States / NINDS NIH HHS / NS / R01 NS028308; United States / NINDS NIH HHS / NS / NS42123; United States / NCI NIH HHS / CA / CA82622; United States / NINDS NIH HHS / NS / NS28308; United States / NINDS NIH HHS / NS / R01 NS042123
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / TWIST1 protein, human; 0 / Twist Transcription Factor
  • [Other-IDs] NLM/ PMC1501937
  •  go-up   go-down


52. Tsai TH, Hwang YF, Hwang SL, Hung CH, Chu CW, Lua BK, Lin CL, Lee KS, Loh JK, Kwan AL, Wang CJ, Huang TY, Howng SL, Lieu AS: Low-grade astrocytoma associated with abscess formation: case report and literature review. Kaohsiung J Med Sci; 2008 May;24(5):262-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade astrocytoma associated with abscess formation: case report and literature review.
  • A rare case of low-grade astrocytoma associated with abscess formation occurred in a 52-year-old man presenting with Broca's aphasia.
  • He underwent craniotomy and tumor removal under the impression of brain tumor with necrotic cystic change.
  • Abscess accumulation within the intra-axial tumor was found intraoperatively.
  • Literature related to brain abscess with brain tumor is reviewed, with an emphasis on abscesses with astrocytoma.
  • We discuss the common brain tumors that are associated with abscess, pathogens that coexist with brain tumor, and the pathogeneses of coexisting brain abscess and tumor.
  • It is very important to know how to differentiate between and diagnose a brain abscess and tumor, or brain abscess with tumor, preoperatively from clinical presentation and through the use of computed tomography, conventional magnetic resonance imaging, diffusion-weighted imaging or magnetic resonance spectroscopy.
  • [MeSH-major] Astrocytoma / complications. Brain Abscess / etiology. Brain Neoplasms / complications
  • [MeSH-minor] Blood-Brain Barrier. Humans. Magnetic Resonance Imaging. Magnetic Resonance Spectroscopy. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18508424.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


53. Shafaati M, Solomon A, Kivipelto M, Björkhem I, Leoni V: Levels of ApoE in cerebrospinal fluid are correlated with Tau and 24S-hydroxycholesterol in patients with cognitive disorders. Neurosci Lett; 2007 Sep 25;425(2):78-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Evidence was recently presented from in vitro studies that 24S-hydroxycholesterol acts as a signalling molecule inducing apoE-mediated cholesterol efflux from astrocytoma cells, and that there is a direct effect of the oxysterol on apoE transcription, protein synthesis and secretion.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Aging / metabolism. Amyloid beta-Peptides / analysis. Amyloid beta-Peptides / cerebrospinal fluid. Biomarkers / analysis. Biomarkers / cerebrospinal fluid. Brain / metabolism. Brain / physiopathology. Cholesterol / metabolism. Female. Humans. Male. Middle Aged. Nerve Degeneration / diagnosis. Nerve Degeneration / metabolism. Nerve Degeneration / physiopathology. Peptide Fragments / analysis. Peptide Fragments / cerebrospinal fluid. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Alzheimer's Disease.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17822846.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Amyloid beta-Peptides; 0 / Apolipoproteins E; 0 / Biomarkers; 0 / Hydroxycholesterols; 0 / Peptide Fragments; 0 / amyloid beta-protein (1-42); 0 / tau Proteins; 47IMW63S3F / 24-hydroxycholesterol; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


54. Vogelbaum MA, Berkey B, Peereboom D, Macdonald D, Giannini C, Suh JH, Jenkins R, Herman J, Brown P, Blumenthal DT, Biggs C, Schultz C, Mehta M: Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol; 2009 Apr;11(2):167-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor tissue was analyzed for the presence of chromosomal deletions on 1p and 19q and for MGMT-promoter methylation.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Astrocytoma / therapy. Brain Neoplasms / therapy. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / therapy. Oligodendroglioma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Combined Modality Therapy. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Dose Fractionation. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Promoter Regions, Genetic. Survival Rate. Treatment Outcome. Tumor Suppressor Proteins / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Treat Rev. 1997 Jan;23(1):35-61 [9189180.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):314-8 [17435180.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):602-7 [8814163.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30 [11020580.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2449-55 [11331324.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4689-92 [11406538.001]
  • [Cites] Neurology. 2001 Jul 24;57(2):340-2 [11468326.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):552-60 [11905710.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):267-73 [12675321.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):271-8 [14558604.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):881-9 [4056902.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4363-7 [9766665.001]
  • (PMID = 18779504.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ PMC2718988
  •  go-up   go-down


55. Pierfelice TJ, Schreck KC, Eberhart CG, Gaiano N: Notch, neural stem cells, and brain tumors. Cold Spring Harb Symp Quant Biol; 2008;73:367-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch, neural stem cells, and brain tumors.
  • Although the role of Notch in neural development is increasingly well understood, it has recently become evident that Notch also has a role in brain tumor biology.
  • Notch receptors are overexpressed in many different brain tumor types, and they may have an initiating role in some.
  • Stem-like cells in brain tumors share many similarities with neural stem/progenitor cells and may require Notch for their survival and growth.
  • Understanding the role of Notch signaling in neoplastic and non-neoplastic stem/progenitor populations will advance our understanding of basic principles regulating developmental and stem cell biology and may also lead to more effective therapies for brain tumors.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Neurons / cytology. Neurons / metabolism. Receptors, Notch / metabolism. Stem Cells / cytology. Stem Cells / metabolism
  • [MeSH-minor] Animals. Astrocytoma / metabolism. Astrocytoma / pathology. Cell Differentiation. Ependymoma / metabolism. Ependymoma / pathology. Humans. Medulloblastoma / metabolism. Medulloblastoma / pathology. Models, Neurological. Neocortex / cytology. Neocortex / growth & development. Neocortex / metabolism. Neoplastic Stem Cells / metabolism. Neoplastic Stem Cells / pathology. Neurogenesis. Signal Transduction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19022772.001).
  • [ISSN] 1943-4456
  • [Journal-full-title] Cold Spring Harbor symposia on quantitative biology
  • [ISO-abbreviation] Cold Spring Harb. Symp. Quant. Biol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS055089
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Notch
  • [Number-of-references] 75
  • [Other-IDs] NLM/ NIHMS376316; NLM/ PMC4510468
  •  go-up   go-down


56. Sega-Pondel D, Wójcik D, Niedzielska E, Niedzielska M, Chybicka A: [Analysis of selected undesirable effects of cytostatic drugs in treatment of the central nervous system tumours in children. Preliminary report]. Med Wieku Rozwoj; 2007 Jul-Sep;11(3 Pt 2):343-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: During treatment of children with brain tumours there is a large risk of occurrence of side effects related to the narrow therapeutic range of cytostatic drugs and irradiation of the central nervous system.
  • MATERIAL AND METHODS: The investigated group consisted of 17 patients (5 girls, 12 boys) aged 1.5-16 yrs, treated for primary brain tumour.
  • Protocol II (etoposide, ifosfamide, adriamycin) in 4 children with glioblastoma multiformae, astrocytoma anaplasticum and ependymoma.
  • Protocol IV (vincristine and carboplatin) in 4 children with astrocytoma fibrillare and astrocytoma pilocyticum.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Cytostatic Agents / adverse effects

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663278.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Cytostatic Agents
  •  go-up   go-down


57. Ueda R, Low KL, Zhu X, Fujita M, Sasaki K, Whiteside TL, Butterfield LH, Okada H: Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma. J Transl Med; 2007 Dec 19;5:68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma.
  • In this report, we characterized GAA-specific CD8+ T cells and innate immune cells in a patient who has survived with anaplastic astrocytoma (AA) for over 12 years without recurrence.
  • RESULTS: The patient's tumor expressed both EphA2 and IL-13Ralpha2, and in vitro stimulated PBMC demonstrated superior EphA2883-891 and IL-13Ralpha2345-353-specific CTL reactivity compared to PBMC samples from two other patients with progressing malignant glioma.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 Oct 14;401(6754):708-12 [10537110.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):577-83 [10649250.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4946-52 [10987311.001]
  • [Cites] J Cell Biol. 2001 Mar 5;152(5):971-84 [11238453.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):909s-916s [11300491.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2851-5 [12231526.001]
  • [Cites] Brain Res Brain Res Rev. 2003 May;42(2):97-122 [12738053.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8874-9 [12847287.001]
  • [Cites] J Immunol. 2003 Nov 1;171(9):4927-33 [14568975.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6946-55 [15501973.001]
  • [Cites] J Exp Med. 1998 Nov 2;188(9):1641-50 [9802976.001]
  • [Cites] Nat Med. 1999 Jun;5(6):677-85 [10371507.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4050-5 [10463606.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):8062-7 [15520217.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Int J Cancer. 2005 Jun 20;115(3):450-5 [15688371.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):6863-71 [15905528.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6 [15980149.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):717-22 [16207473.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4943-51 [16651452.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5883-91 [16740728.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Science. 2006 Oct 6;314(5796):126-9 [16946036.001]
  • [Cites] J Invest Dermatol. 2007 Mar;127(3):622-9 [17039243.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1842-52 [17293384.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1204-12 [17476350.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):203-14 [17541944.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Nat Med. 2007 Sep;13(9):1050-9 [17704786.001]
  • [Cites] Cancer Immunol Immunother. 2007 Dec;56(12):1931-43 [17522860.001]
  • (PMID = 18093336.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA100327; United States / NINDS NIH HHS / NS / P01 NS040923; United States / NINDS NIH HHS / NS / P01 NS40923
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / HLA-A2 Antigen
  • [Other-IDs] NLM/ PMC2244605
  •  go-up   go-down


58. Lee WH, Jin JS, Tsai WC, Chen YT, Chang WL, Yao CW, Sheu LF, Chen A: Biological inhibitory effects of the Chinese herb danggui on brain astrocytoma. Pathobiology; 2006;73(3):141-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological inhibitory effects of the Chinese herb danggui on brain astrocytoma.
  • In nude mice, the growth of the tumor was inhibited by 30% by AS-CH or AS-AC (20 mg/kg; p < 0.05) and by 60% by AS-CH or AS-AC (60 mg/kg; p < 0.05).
  • CONCLUSIONS: Danggui may inhibit tumor growth by reducing the level of VEGF and the proapoptotic protein, cathepsin B.
  • [MeSH-major] Angelica sinensis / chemistry. Antineoplastic Agents / pharmacology. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Drugs, Chinese Herbal / pharmacology. Phytotherapy
  • [MeSH-minor] Adult. Animals. Apoptosis / drug effects. Cathepsin B / metabolism. Cell Line, Tumor. Cell Survival / drug effects. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Female. Formazans / metabolism. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Transplantation. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / pathology. Plant Extracts / pharmacology. Tetrazolium Salts / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085958.001).
  • [ISSN] 1015-2008
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Chinese Herbal; 0 / Formazans; 0 / Plant Extracts; 0 / Tetrazolium Salts; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 23305-68-2 / MTT formazan; EC 3.4.22.1 / Cathepsin B
  •  go-up   go-down


59. Martín R, Ibeas E, Carvalho-Tavares J, Hernández M, Ruiz-Gutierrez V, Nieto ML: Natural triterpenic diols promote apoptosis in astrocytoma cells through ROS-mediated mitochondrial depolarization and JNK activation. PLoS One; 2009;4(6):e5975
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural triterpenic diols promote apoptosis in astrocytoma cells through ROS-mediated mitochondrial depolarization and JNK activation.
  • However, the antineoplastic activity of two natural occurring triterpenoid alcohols extracted from olive oil, erythrodiol (an intermediate from oleanolic acid), and its isomer, uvaol, has barely been reported, particularly on brain cancer cells.
  • Astrocytomas are among the most common and aggressive type of primary malignant tumors in the neurological system lacking effective treatments, and in this study, we addressed the effect of these two triterpenic diols on the human 1321N1 astrocytoma cell line.
  • CONCLUSIONS: Overall, we provide a significant insight into the anticarcinogenic action of erythrodiol and uvaol that may have a potential in prevention and treatment of brain tumors and other cancers.
  • [MeSH-major] Apoptosis. Astrocytoma / drug therapy. Astrocytoma / pathology. Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. MAP Kinase Kinase 4 / metabolism. Mitochondria / metabolism. Reactive Oxygen Species. Terpenes / chemistry
  • [MeSH-minor] Cell Line, Tumor. Cell Survival. Drug Screening Assays, Antitumor. Humans. Membrane Potentials. Oleanolic Acid / analogs & derivatives. Oleanolic Acid / chemistry. Triterpenes / pharmacology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2006 Nov 27;580(27):6302-10 [17083937.001]
  • [Cites] Cancer Lett. 1997 Jan 1;111(1-2):7-13 [9022122.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2816-23 [17363604.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3741-51 [17440087.001]
  • [Cites] Indian J Exp Biol. 2007 May;45(5):425-31 [17569283.001]
  • [Cites] J Neurooncol. 2007 Sep;84(2):147-57 [17361329.001]
  • [Cites] Pharmacol Biochem Behav. 2008 Oct;90(4):712-6 [18582921.001]
  • [Cites] Endocrinology. 1997 Sep;138(9):3849-58 [9275074.001]
  • [Cites] J Agric Food Chem. 1999 Apr;47(4):1558-62 [10564016.001]
  • [Cites] Nat Cell Biol. 1999 Sep;1(5):E131-8 [10559956.001]
  • [Cites] Int J Oncol. 2000 Apr;16(4):651-62 [10717232.001]
  • [Cites] J Neurosci. 2000 Jun 15;20(12):4506-14 [10844020.001]
  • [Cites] J Neurooncol. 2000;46(2):97-103 [10894362.001]
  • [Cites] Trends Cell Biol. 2000 Sep;10(9):369-77 [10932094.001]
  • [Cites] J Med Chem. 2000 Nov 2;43(22):4233-46 [11063620.001]
  • [Cites] Neuro Oncol. 2001 Oct;3(4):229-40 [11584892.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2603-14 [11675328.001]
  • [Cites] Cancer Lett. 2002 Mar 8;177(1):7-12 [11809525.001]
  • [Cites] Drug Resist Updat. 2001 Aug;4(4):233-42 [11991678.001]
  • [Cites] Apoptosis. 2002 Jun;7(3):247-60 [11997669.001]
  • [Cites] J Cell Biol. 2002 Jun 24;157(7):1233-45 [12082081.001]
  • [Cites] Arzneimittelforschung. 2002;52(11):797-802 [12489249.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Jan;4(1):33-45 [12511867.001]
  • [Cites] Phytomedicine. 2003 Mar;10(2-3):115-21 [12725563.001]
  • [Cites] Planta Med. 2003 May;69(5):472-4 [12802735.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2866-75 [12855667.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Aug 8;307(4):1029-37 [12878215.001]
  • [Cites] Life Sci. 2004 Apr 16;74(22):2769-79 [15043991.001]
  • [Cites] Biochem J. 1997 Aug 15;326 ( Pt 1):1-16 [9337844.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4956-64 [9354463.001]
  • [Cites] J Biol Chem. 1998 Jan 2;273(1):606-12 [9417122.001]
  • [Cites] Physiol Rev. 1998 Jul;78(3):763-81 [9674694.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1312-6 [9721091.001]
  • [Cites] J Cell Biol. 1998 Sep 7;142(5):1381-91 [9732297.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Jun;289(3):1306-12 [10336521.001]
  • [Cites] J Cell Biol. 1999 Jun 14;145(6):1293-307 [10366600.001]
  • [Cites] FEBS Lett. 1999 Jun 25;453(3):356-60 [10405175.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):421-8 [15701824.001]
  • [Cites] Mol Cancer Ther. 2005 Mar;4(3):381-8 [15767547.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):823-30 [16077934.001]
  • [Cites] J Agric Food Chem. 2006 Mar 22;54(6):2096-102 [16536581.001]
  • [Cites] J Nutr. 2006 Oct;136(10):2553-7 [16988125.001]
  • [Cites] Phytomedicine. 2004 Feb;11(2-3):121-9 [15070161.001]
  • [Cites] Exp Mol Pathol. 2004 Aug;77(1):18-25 [15215046.001]
  • [Cites] Life Sci. 2004 Sep 24;75(19):2303-16 [15350828.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Aug 27;321(3):539-46 [15358141.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7570-8 [15492284.001]
  • [Cites] J Nat Prod. 2004 Oct;67(10):1697-700 [15497942.001]
  • [Cites] Anal Biochem. 1969 Jul;30(1):7-24 [4240294.001]
  • [Cites] J Appl Bacteriol. 1990 Jun;68(6):587-91 [2118130.001]
  • [Cites] Planta Med. 1992 Dec;58(6):513-5 [1484890.001]
  • [Cites] Cell. 1994 Aug 26;78(4):539-42 [8069905.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1449-56 [7533326.001]
  • [Cites] Exp Cell Res. 1995 Jul;219(1):15-20 [7628531.001]
  • [Cites] Science. 1995 Nov 24;270(5240):1326-31 [7481820.001]
  • [Cites] J Nat Prod. 1996 Jul;59(7):643-5 [8759159.001]
  • [Cites] Biosci Biotechnol Biochem. 2007 Jan;71(1):31-7 [17213663.001]
  • (PMID = 19543395.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; 0 / Terpenes; 0 / Triterpenes; 545-48-2 / erythrodiol; 6SMK8R7TGJ / Oleanolic Acid; EC 2.7.12.2 / MAP Kinase Kinase 4; W599R31ROT / uvaol
  • [Other-IDs] NLM/ PMC2695006
  •  go-up   go-down


60. Santamaría A, Martínez R, Astigarraga I, Etxebarría J, Sánchez M: [Ophthalmological findings in pediatric brain neoplasms: 58 cases]. Arch Soc Esp Oftalmol; 2008 Aug;83(8):471-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ophthalmological findings in pediatric brain neoplasms: 58 cases].
  • PURPOSES: To describe the visual manifestations of brain neoplasms, and to analyze the effect of tumor control on these.
  • METHODS: This is a descriptive retrospective study, which includes patients under 14 years of age, suffering from different brain neoplasms in our hospital between 1996 and 2005 inclusive.
  • In 28% of cases, the amblyopia was secondary to the strabismus/nystagmus produced by the developing tumor.
  • Ophthalmologic evaluation (including perimetry and fundoscopy) enabled detection of 3 tumor relapses.
  • CONCLUSIONS: Visual analysis (visual acuity, perimetry, fundoscopy) should be an essential component of assessment during brain neoplasm treatment and follow-up.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Eye Diseases / etiology. Fundus Oculi. Vision Disorders / etiology. Visual Acuity. Visual Field Tests
  • [MeSH-minor] Adolescent. Age Factors. Amblyopia / etiology. Child. Child, Preschool. Follow-Up Studies. Humans. Hyperopia / diagnosis. Hyperopia / etiology. Infant. Infant, Newborn. Nystagmus, Pathologic / diagnosis. Nystagmus, Pathologic / etiology. Retrospective Studies. Strabismus / etiology. Visual Fields


61. Glotsos D, Tohka J, Ravazoula P, Cavouras D, Nikiforidis G: Automated diagnosis of brain tumours astrocytomas using probabilistic neural network clustering and support vector machines. Int J Neural Syst; 2005 Feb-Apr;15(1-2):1-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Automated diagnosis of brain tumours astrocytomas using probabilistic neural network clustering and support vector machines.
  • A computer-aided diagnosis system was developed for assisting brain astrocytomas malignancy grading.
  • Microscopy images from 140 astrocytic biopsies were digitized and cell nuclei were automatically segmented using a Probabilistic Neural Network pixel-based clustering algorithm.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Diagnosis, Computer-Assisted / methods. Neural Networks (Computer)

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15912578.001).
  • [ISSN] 0129-0657
  • [Journal-full-title] International journal of neural systems
  • [ISO-abbreviation] Int J Neural Syst
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P41 RR013642; United States / NCRR NIH HHS / RR / U54 RR021813
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Singapore
  •  go-up   go-down


62. Clarke MJ, Foy AB, Wetjen N, Raffel C: Imaging characteristics and growth of subependymal giant cell astrocytomas. Neurosurg Focus; 2006;20(1):E5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Resection was recommended for symptomatic and neuroimaging evidence of hydrocephalus (41%), tumor growth without evidence of hydrocephalus (33%), and for poorly controlled seizures (25%).
  • The mean diameter of the tumors at the time of resection was 1.9 cm (range 0.3-4 cm), and no tumor recurred.
  • Tumor growth and contrast enhancement are the most common signs of progression on neuroimages, and may be seen prior to the development of obstructive hydrocephalus.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16459995.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Hoang-Xuan K, Idbaih A, Mokhtari K, Sanson M: [Towards a molecular classification of gliomas]. Bull Cancer; 2005 Apr;92(4):310-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Molecular profiles have been associated with specific histologic and prognostic tumor subgroups, contributing to improve the classification of gliomas.
  • At least two alternative molecular pathways have been suggested in the astrocytoma progression involving TP53 inactivation (secondary glioblastomas) and EGFR amplification (de novo glioblastomas) respectively.
  • Oligodendroglial tumors have demonstrated recurrent combined loss of chromosome 1p/19q, which represent a favorable prognosis marker and probably a predictor of a good chemosensitivity of the tumor.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosome Aberrations. Glioma / genetics
  • [MeSH-minor] Astrocytoma / genetics. Astrocytoma / pathology. Chromosome Deletion. Chromosomes, Human, Pair 1. Genes, erbB-1 / genetics. Genes, p53 / genetics. Humans. Oligodendroglioma / genetics. Oligodendroglioma / pathology. Prognosis


64. Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ, Holmes EJ, Zhou T, Finlay JL: O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol; 2006 Jul 20;24(21):3431-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort.
  • PURPOSE: O6-methylguanine-DNA methyltransferase (MGMT) functions to counteract the cytotoxic effects of alkylating agents, such as nitrosoureas, which play a central role in the treatment of childhood malignant gliomas.
  • Epigenetic silencing of MGMT has been associated with prolonged survival in adults with malignant gliomas, although the association between MGMT expression status and outcome in pediatric malignant gliomas has not been defined.
  • METHODS: We examined the association between MGMT expression and survival duration using tumor samples from the Children's Cancer Group 945 study, the largest randomized trial for childhood malignant gliomas completed to date.
  • RESULTS: Twelve of the 109 samples demonstrated overexpression of MGMT compared with normal brain.
  • The association between MGMT overexpression and adverse outcome remained significant after stratifying for institutional histologic diagnosis (eg, anaplastic astrocytoma or glioblastoma multiforme), as well as age, amount of residual tumor, and tumor location.
  • CONCLUSION: Overexpression of MGMT in childhood malignant gliomas is strongly associated with an adverse outcome in children treated with alkylator-based chemotherapy, independently of a variety of clinical prognostic factors.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Biomarkers, Tumor / metabolism. Brain Neoplasms / drug therapy. Brain Neoplasms / enzymology. Glioma / drug therapy. Glioma / enzymology. O(6)-Methylguanine-DNA Methyltransferase / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16849758.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA13539; United States / NINDS NIH HHS / NS / NS37704
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers, Tumor; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


65. Rüweler M, Anker A, Gülden M, Maser E, Seibert H: Inhibition of peroxide-induced radical generation by plant polyphenols in C6 astroglioma cells. Toxicol In Vitro; 2008 Aug;22(5):1377-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Flavonoids / pharmacology. Free Radical Scavengers / pharmacology. Oxidative Stress / drug effects. Phenols / pharmacology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. GENISTEIN .
  • Hazardous Substances Data Bank. RESVERATROL .
  • Hazardous Substances Data Bank. CUMENE HYDROPEROXIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18406568.001).
  • [ISSN] 0887-2333
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzene Derivatives; 0 / Flavonoids; 0 / Free Radical Scavengers; 0 / Free Radicals; 0 / Oxidants; 0 / Phenols; 0 / Plant Extracts; 0 / Polyphenols; 0 / Stilbenes; 142FWE6ECS / galangin; DH2M523P0H / Genistein; KUX1ZNC9J2 / Luteolin; PG7JD54X4I / cumene hydroperoxide; Q369O8926L / resveratrol
  •  go-up   go-down


66. Adamson DC, Rasheed BA, McLendon RE, Bigner DD: Central nervous system. Cancer Biomark; 2010;9(1-6):193-210
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several different types of tumors, benign and malignant, have been identified in the central nervous system (CNS).
  • The prognoses for these tumors are related to several factors, such as the age of the patient and the location and histology of the tumor.
  • In adults, about half of all CNS tumors are malignant, whereas in pediatric patients, more than 75% are malignant.
  • Unfortunately, we still lack effective treatments for most primary and secondary malignant CNS tumors.
  • However, the past decade has witnessed an explosion in the understanding of the early molecular events in malignant primary CNS tumors, and for the first time in history, oncologists are seeing that a plethora of new therapies targeting these molecular events are being tested in clinical trials.
  • Other much less common sites of primary CNS tumors include the pineal region, ventricular system, cerebellum, brain stem, cranial nerves, and spinal cord.
  • The distribution of CNS tumors by histology has seen a slight increase in more malignant tumors over the past decade, possibly due to increased neuroimaging practices or environmental exposures.
  • Grade IV, the most malignant grade of astrocytoma, includes glioblastoma multiforme (GBM), the most common malignant primary CNS glioma in adults, which represents 51% of all CNS gliomas.
  • Here we describe the molecular and cellular events associated with malignant glioma initiation and progression.
  • We also review the importance of glioma stem cell biology and tumor immunology in early gliomagenesis.
  • In addition, we present a brief description of the most common malignant primary CNS glioma in pediatric patients - medulloblastoma, as well as familial cancer syndromes that include gliomas as part of the syndrome.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22112477.001).
  • [ISSN] 1875-8592
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  •  go-up   go-down


67. Rachinger W, Grau S, Holtmannspötter M, Herms J, Tonn JC, Kreth FW: Serial stereotactic biopsy of brainstem lesions in adults improves diagnostic accuracy compared with MRI only. J Neurol Neurosurg Psychiatry; 2009 Oct;80(10):1134-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of the current prospective study was to analyse the validity of MRI based diagnosis of brainstem gliomas which was verified by stereotactic biopsy and follow-up evaluation as well as to assess prognostic factors and risk profile.
  • The MRI based diagnosis of the lesions was made independently by an experienced neuroradiologist.
  • Histological evaluation revealed pilocytic astrocytoma (n = 2), WHO grade II glioma (n = 14), malignant glioma (n = 12), metastasis (n = 7), lymphoma (n = 5), cavernoma (n = 1), inflammatory disease (n = 2) or no tumour/gliosis (n = 3).
  • All patients with "no tumour" or "inflammatory disease" survived.
  • Patients with low grade glioma and malignant glioma showed a 1 year survival rate of 75% and 25%, respectively; the 1 year survival rate for patients with lymphoma or metastasis was 30%.
  • In the subgroup with a verified brainstem glioma, negative predictors for length of survival were higher tumour grade (p = 0.002) and Karnofsky performance score < or =70 (p = 0.004).
  • CONCLUSION: Intra-axial brainstem lesions with a radiological pattern of glioma represent a very heterogeneous tumour group with completely different outcomes.
  • Stereotactic biopsy is a safe method to obtain a valid tissue diagnosis, which is indispensible for treatment decision.
  • [MeSH-major] Biopsy / methods. Brain Stem Neoplasms / pathology. Glioma / pathology. Magnetic Resonance Imaging. Stereotaxic Techniques

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19520698.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


68. Parsa CF, Givrad S: Pilocytic astrocytomas as hamartomas: implications for treatment. Br J Ophthalmol; 2008 Jan;92(1):3-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Astrocytoma / therapy. Brain Diseases / therapy. Brain Neoplasms / therapy. Hamartoma / therapy

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156370.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


69. Antonelli M, Buttarelli FR, Arcella A, Nobusawa S, Donofrio V, Oghaki H, Giangaspero F: Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J Neurooncol; 2010 Sep;99(2):209-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to evaluate, in a series of 43 pediatric high-grade gliomas (21 anaplastic astrocytoma WHO grade III and 22 glioblastoma WHO grade IV), the prognostic value of histological grading and expression of p53 and YKL-40.
  • TP53 mutations were detected in five of 27 (18%) cases (four glioblastomas and one anaplastic astrocytoma).
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / metabolism. Glycoproteins / metabolism. Isocitrate Dehydrogenase / genetics. Lectins / metabolism. Mutation / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adipokines. Adolescent. Adult. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Child. Child, Preschool. Chitinase-3-Like Protein 1. DNA, Neoplasm / genetics. Female. Humans. Immunoenzyme Techniques. Infant. Infant, Newborn. Male. Neoplasm Staging. Polymerase Chain Reaction. Prognosis. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Oncol Rep. 2009 Jan;11(1):68-72 [19080744.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):267-72 [16195804.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3155-64 [11753995.001]
  • [Cites] Neuro Oncol. 2009 Aug;11(4):341-7 [19435942.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):888-93 [17554787.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4150-4 [19636000.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Biochem J. 2002 Jul 1;365(Pt 1):119-26 [12071845.001]
  • [Cites] Hum Pathol. 1999 Nov;30(11):1284-90 [10571506.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):597-602 [18985363.001]
  • [Cites] N Engl J Med. 2009 May 21;360(21):2248; author reply 2249 [19458374.001]
  • [Cites] Neuro Oncol. 2009 Jun;11(3):274-80 [18981259.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3326-34 [15867231.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):49-56 [15118874.001]
  • [Cites] J Neurosurg. 1991 Jan;74(1):27-37 [1984503.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12 (13):3935-41 [16818690.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6002-7 [19755387.001]
  • [Cites] Curr Probl Cancer. 2008 May-Jun;32(3):97-123 [18501774.001]
  • [Cites] Recent Results Cancer Res. 2009;171:67-81 [19322538.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):765-73 [19228619.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1525-32 [11290570.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1196-208 [17401009.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7404-7 [11606370.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):121-30 [8988090.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):264-71 [11815986.001]
  • [Cites] Neurosurgery. 1995 Aug;37(2):246-54 [7477776.001]
  • [Cites] Exp Cell Res. 1999 Jul 10;250(1):168-73 [10388530.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6284-92 [17975139.001]
  • (PMID = 20174854.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adipokines; 0 / CHI3L1 protein, human; 0 / Chitinase-3-Like Protein 1; 0 / DNA, Neoplasm; 0 / Glycoproteins; 0 / Lectins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human
  •  go-up   go-down


70. Feiden S, Feiden W: [WHO classification of tumours of the CNS: revised edition of 2007 with critical comments on the typing und grading of common-type diffuse gliomas]. Pathologe; 2008 Nov;29(6):411-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six new entities were codified: angiocentric glioma (AG); papillary glioneuronal tumour (PGNT); rosette-forming glioneuronal tumour of the fourth ventricle (RGNT); papillary tumour of the pineal region (PTPR); spindle cell oncocytoma of the adenohypophysis (SCO); and pituicytoma.
  • Furthermore, six histological variants of well-known brain tumours have been added, partially because they show different biological behaviour and/or prognosis: pilomyxoid astrocytoma; atypical choroid plexus papilloma; medulloblastoma with extensive nodularity; anaplastic medulloblastoma; extraventricular neurocytoma; non-specific variant of dysembryoplastic neuroepithelial tumour (DNT).
  • Moreover, the typing und grading of common-type diffuse gliomas, as well as the WHO grading system, are critically reviewed, particularly with regard to the prognostically important differential diagnosis of diffuse astrocytomas und oligodendrogliomas.
  • [MeSH-major] Brain Neoplasms / pathology. Central Nervous System Neoplasms / classification. Central Nervous System Neoplasms / pathology. Glioma / classification. Glioma / pathology
  • [MeSH-minor] Astrocytoma / classification. Astrocytoma / pathology. Choroid Neoplasms / classification. Choroid Neoplasms / pathology. Humans. Medulloblastoma / classification. Medulloblastoma / pathology. Oligodendroglioma / classification. Oligodendroglioma / pathology. Papilloma / classification. Papilloma / pathology. World Health Organization

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]
  • [Cites] J Neurooncol. 1999 Feb;41(3):267-80 [10359147.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):89-96 [15146346.001]
  • [Cites] Acta Pathol Microbiol Scand. 1950;27(1):51-64 [15406242.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Pathologe. 1998 Jul;19(4):259-68 [9746910.001]
  • [Cites] Brain Pathol. 2007 Jul;17(3):308-13 [17598823.001]
  • [Cites] J Neurosurg. 1999 Dec;91(6):971-7 [10584843.001]
  • [Cites] Pathologe. 2008 Nov;29(6):422-7 [18779965.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1069-73 [17086103.001]
  • [Cites] Brain Pathol. 2007 Jul;17(3):314-8 [17598824.001]
  • [Cites] Brain Pathol. 2007 Jul;17(3):319-24 [17598825.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1949 Feb 2;24(3):71-5 [18111063.001]
  • [Cites] Brain Pathol. 2007 Jul;17(3):304-7 [17598822.001]
  • (PMID = 18820922.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


71. Arai A, Sasayama T, Tamaki M, Sakagami Y, Enoki E, Ohbayashi C, Kohmura E: Rosette-forming glioneuronal tumor of the fourth ventricle--case report. Neurol Med Chir (Tokyo); 2010;50(3):224-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rosette-forming glioneuronal tumor of the fourth ventricle--case report.
  • Rosette-forming glioneuronal tumor (RGNT) of the fourth ventricle is a rare tumor included as a novel glioneuronal neoplasm in the 2007 World Health Organization classification of brain tumors.
  • The tumor was gross totally resected.
  • RGNT of the fourth ventricle should be considered in the differential diagnosis of infratentorial lesions in young adults.
  • The prognosis is benign, but relatively aggressive behaviors such as tumor growth, recurrence, and acute deterioration due to intratumoral hemorrhaging can occur.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Fourth Ventricle / pathology. Infratentorial Neoplasms / pathology. Neoplasms, Neuroepithelial / pathology. Teratoma / pathology
  • [MeSH-minor] Adolescent. Astrocytoma / pathology. Female. Ganglioglioma / pathology. Humans. Rare Diseases / pathology. Rosette Formation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20339273.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


72. Odreman F, Vindigni M, Gonzales ML, Niccolini B, Candiano G, Zanotti B, Skrap M, Pizzolitto S, Stanta G, Vindigni A: Proteomic studies on low- and high-grade human brain astrocytomas. J Proteome Res; 2005 May-Jun;4(3):698-708
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic studies on low- and high-grade human brain astrocytomas.
  • Human brain astrocytomas range from the indolent low-grade to the highly infiltrating and aggressive high-grade form, also known as glioblastoma multiforme.
  • The extensive heterogeneity of astrocytic tumors complicates their pathological classification.
  • These data provide an initial reference map for brain gliomas.
  • [MeSH-major] Astrocytoma / chemistry. Neoplasm Proteins / analysis. Proteomics
  • [MeSH-minor] Blotting, Western. Brain Neoplasms / chemistry. Electrophoresis, Gel, Two-Dimensional. Gene Expression Regulation, Neoplastic. Glioblastoma / chemistry. Humans. Immunohistochemistry. Mass Spectrometry

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15952716.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


73. Skardelly M, Armbruster FP, Meixensberger J, Hilbig H: Expression of Zonulin, c-kit, and Glial Fibrillary Acidic Protein in Human Gliomas. Transl Oncol; 2009 Aug 18;2(3):117-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The hallmarks of human malignant gliomas are their marked invasiveness and vascularity.
  • Because angiogenesis and tumor invasion have been associated with extracellular matrix degradation and intercellular tight junctions, the involvement of zonulin in glioma biology is in the focus.
  • We selected for histological examination five cases of glioblastoma WHO IV (nomenclature of the World Health Organization) and one case each from astrocytoma WHO III, meningioma WHO III, and meningioma WHO I as control samples.
  • The meningioma WHO I is regarded as benign, whereas the meningioma WHO III is recognized as the transition form of malignant tumors in humans.
  • Both are correlated to the degree of malignancy of human brain tumors.
  • The expression of zonulin is correlated to the degradation of the blood-brain barrier as revealed by Griffonia simplicifolia lectin.
  • In differently graded tumors, we found differently graded involvement of blood vessels in the tumor development, explaining patients' survival.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Gastroenterol. 2006 Apr;41(4):408-19 [16635908.001]
  • [Cites] Clin Neuropathol. 2006 May-Jun;25(3):107-14 [16719406.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):105-9 [16205964.001]
  • [Cites] J Neurooncol. 2005 Nov;75(2):163-7 [16132509.001]
  • [Cites] J Neurooncol. 2005 Nov;75(2):195-202 [16132504.001]
  • [Cites] J Clin Invest. 1989 Feb;83(2):724-7 [2492310.001]
  • [Cites] J Clin Invest. 1989 Apr;83(4):1089-94 [2649511.001]
  • [Cites] Infect Immun. 2003 Apr;71(4):1897-902 [12654806.001]
  • [Cites] Gut. 2003 Feb;52(2):218-23 [12524403.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1607-15 [12404235.001]
  • [Cites] Ann N Y Acad Sci. 2000;915:214-22 [11193578.001]
  • [Cites] J Biol Chem. 2001 Jun 1;276(22):19160-5 [11278543.001]
  • [Cites] J Cell Sci. 2000 Dec;113 Pt 24:4435-40 [11082037.001]
  • [Cites] Curr Opin Gastroenterol. 2008 Nov;24(6):687-91 [19122516.001]
  • [Cites] J Pathol. 2007 Mar;211(4):481-8 [17294421.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):287-300 [16616334.001]
  • (PMID = 19701495.001).
  • [ISSN] 1936-5233
  • [Journal-full-title] Translational oncology
  • [ISO-abbreviation] Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2730142
  •  go-up   go-down


74. Massimi L, Caldarelli M, D'Alessandris QG, Rollo M, Lauriola L, Giangaspero F, Di Rocco C: 12-year-old boy with multiple brain masses. Brain Pathol; 2010 May;20(3):679-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 12-year-old boy with multiple brain masses.
  • The occurrence of more than one brain tumor in a single patient is not new, resulting from RT- or CT-induced neoplasms, syndromes or casual association.
  • We report on the exceptional case of a 12-year-old boy harboring three different brain tumors with no definite correlation.
  • The first MRI showed a medulloblastoma with signs of infratentorial and supratentorial tumor spreading, including a small frontal mass.
  • Finally, the possible local recurrence of the original medulloblastoma was a pilocytic astrocytoma with post-radiation alterations.
  • Explanations of this very unusual association include radio-induced tumors, second tumors developing from remnants of medulloblastoma cancer stem cells, or the changing histology after adjuvant therapy.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cerebellar Neoplasms / pathology. Medulloblastoma / pathology. Neoplasms, Multiple Primary / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20522094.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


75. Hu H, Chen G, Zhang JM, Zhang WP, Zhang L, Ge QF, Yao HT, Ding W, Chen Z, Wei EQ: Distribution of cysteinyl leukotriene receptor 2 in human traumatic brain injury and brain tumors. Acta Pharmacol Sin; 2005 Jun;26(6):685-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of cysteinyl leukotriene receptor 2 in human traumatic brain injury and brain tumors.
  • METHODS: Brain specimens were obtained from patients who underwent brain surgery.
  • CysLT2 in brain tissues was examined using immunohistochemical analysis.
  • CysLT2 was also expressed in the granulocytes in both vessels and in the brain parenchyma.
  • CONCLUSION: CysLT2 is distributed in vascular smooth muscle cells and granulocytes, and brain trauma and tumor can induce its expression in vascular endothelial cells and in a number of other cells.
  • [MeSH-major] Brain Injuries / metabolism. Brain Neoplasms / metabolism. Endothelial Cells / metabolism. Membrane Proteins / metabolism. Myocytes, Smooth Muscle / metabolism. Receptors, Leukotriene / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Astrocytoma / metabolism. Astrocytoma / pathology. Brain / blood supply. Brain / metabolism. Female. Ganglioglioma / metabolism. Ganglioglioma / pathology. Granulocytes / metabolism. Humans. Male. Microcirculation / pathology. Middle Aged. Muscle, Smooth, Vascular / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Guide to Pharmacology. gene/protein/disease-specific - CysLT2 receptor - data and references .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15916734.001).
  • [ISSN] 1671-4083
  • [Journal-full-title] Acta pharmacologica Sinica
  • [ISO-abbreviation] Acta Pharmacol. Sin.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Receptors, Leukotriene; 0 / cysteinyl leukotriene receptor 2
  •  go-up   go-down


76. Akar S, Drappatz J, Hsu L, Blinder RA, Black PM, Kesari S: Hypertrophic olivary degeneration after resection of a cerebellar tumor. J Neurooncol; 2008 May;87(3):341-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypertrophic olivary degeneration after resection of a cerebellar tumor.
  • We report a case of hypertrophic olivary degeneration due to cerebellar surgery for a low-grade tumor.
  • A 27-year-old female presented with right-sided paresthesias and intermittent leg paresis following a right cerebellar resection of a tumor 2 weeks prior.
  • Hypertrophic olivary degeneration may be mistaken for tumor progression, post-operative vasculopathy or granulation tissue and should be considered in patients undergoing cerebellar surgery.
  • [MeSH-major] Astrocytoma / surgery. Cerebellar Neoplasms / surgery. Neurosurgical Procedures / adverse effects. Olivary Nucleus / pathology
  • [MeSH-minor] Adult. Ataxia / etiology. Diagnosis, Differential. Female. Humans. Hypertrophy. Hypesthesia / etiology. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Cerebellar Degeneration.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arq Neuropsiquiatr. 2003 Jun;61(2B):473-7 [12894288.001]
  • [Cites] J Neurosurg. 2004 Apr;100(4):717 [15070130.001]
  • [Cites] Mov Disord. 1997 May;12(3):432-7 [9159743.001]
  • [Cites] Acta Neuropathol. 1981;54(4):275-82 [7270084.001]
  • [Cites] Brain. 2002 Jun;125(Pt 6):1348-57 [12023323.001]
  • [Cites] Clin Imaging. 1999 Jul-Aug;23(4):215-7 [10631896.001]
  • [Cites] Eur J Paediatr Neurol. 2007 Jul;11(4):232-4 [17400009.001]
  • [Cites] Neuroradiology. 1993;35(5):335-8 [8327105.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Jun;74(6):797-9 [12754356.001]
  • [Cites] Arq Neuropsiquiatr. 2005 Jun;63(2A):321-3 [16100982.001]
  • [Cites] Radiology. 1999 Dec;213(3):814-7 [10580959.001]
  • [Cites] Pediatr Radiol. 1998 Nov;28(11):830-1 [9799311.001]
  • [Cites] Eur Neurol. 1998;39(2):97-102 [9520070.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Jun-Jul;21(6):1073-7 [10871017.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Oct;15(9):1715-9 [7847219.001]
  • [Cites] Neurology. 1991 Apr;41(4):557-62 [2011257.001]
  • [Cites] Radiology. 1994 Aug;192(2):539-43 [8029428.001]
  • (PMID = 18217209.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Lin C, Ma L, Yin J, Chen J: [A medical image semantic modeling based on hierarchical Bayesian networks]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Apr;26(2):400-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As for the validity of this method, we have built a multi-level semantic model from a small set of astrocytoma MRI (magnetic resonance imaging) samples, in order to extract semantics of astrocytoma in malignant degree.
  • [MeSH-minor] Artificial Intelligence. Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Humans. Image Interpretation, Computer-Assisted / methods. Semantics

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19499811.001).
  • [ISSN] 1001-5515
  • [Journal-full-title] Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi
  • [ISO-abbreviation] Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


78. Maris C, Rorive S, Sandras F, D'Haene N, Sadeghi N, Bièche I, Vidaud M, Decaestecker C, Salmon I: Tenascin-C expression relates to clinicopathological features in pilocytic and diffuse astrocytomas. Neuropathol Appl Neurobiol; 2008 Jun;34(3):316-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Tenascin-C (TN-C) is an extracellular matrix brain glycoprotein for which conflicting in vitro and in vivo results are reported in the literature dealing with its involvement in astrocytoma aggressiveness, in particular astrocytoma invasion.
  • METHODS: Using real-time reverse transcription polymerase chain reaction and immunohistochemistry, we analysed the TN-C expression in normal brain tissue as well as in a series of 54 pilocytic and 53 grade II astrocytomas.
  • CONCLUSIONS: Our data on normal brain showed that while TN-C is largely expressed in supratentorial white matter, it was largely absent in infratentorial white matter.
  • Paralleling these observations, we showed that TN-C expression in low-grade astrocytomas similarly varies according to tumour site.
  • RESULTS: Similarly to normal brain, low-grade astrocytomas exhibit variations in TN-C expression with site, and this expression is associated with an independent prognostic value in terms of recurrence.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Tenascin / biosynthesis
  • [MeSH-minor] Adult. Age Factors. Biomarkers, Tumor / analysis. Child. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Neoplasm Recurrence, Local / pathology. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Spinal Cord Neoplasms / metabolism. Spinal Cord Neoplasms / mortality. Spinal Cord Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17983425.001).
  • [ISSN] 1365-2990
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tenascin
  •  go-up   go-down


79. Grand SD, Kremer S, Tropres IM, Hoffmann DM, Chabardes SJ, Lefournier V, Berger FR, Pasteris C, Krainik A, Pasquier BM, Peoch M, Le Bas JF: Perfusion-sensitive MRI of pilocytic astrocytomas: initial results. Neuroradiology; 2007 Jul;49(7):545-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Various areas of relative cerebral blood volume (rCBV) within the tumors were obtained.
  • The maximum rCBV ratios were identified and considered as representative of the tumor.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / physiopathology. Blood Volume. Brain Neoplasms / diagnosis. Brain Neoplasms / physiopathology. Magnetic Resonance Angiography

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2004 Feb;25(2):214-21 [14970020.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1479-86 [9843274.001]
  • [Cites] AJR Am J Roentgenol. 1989 Jun;152(6):1263-70 [2718863.001]
  • [Cites] J Neuroradiol. 2002 Jun;29(2):105-13 [12297732.001]
  • [Cites] AJR Am J Roentgenol. 1993 Aug;161(2):369-72 [8333380.001]
  • [Cites] Invest Radiol. 2002 Oct;37(10):571-6 [12352166.001]
  • [Cites] Neurosci Lett. 2003 Feb 27;338(2):119-22 [12566167.001]
  • [Cites] J Neurosurg. 1986 Nov;65(5):592-9 [3772444.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2003 Aug;11(3):403-13 [14768726.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 May;21(5):901-9 [10815666.001]
  • [Cites] Radiology. 1993 Oct;189(1):221-5 [8372197.001]
  • [Cites] Radiology. 1993 Oct;189(1):233-8 [8372199.001]
  • [Cites] Zh Vopr Neirokhir Im N N Burdenko. 2005 Jan-Mar;(1):20-4; discussion 24 [15912865.001]
  • [Cites] J Comput Assist Tomogr. 1999 Mar-Apr;23(2):232-7 [10096330.001]
  • [Cites] Pediatr Neurosci. 1989;15(3):105-10 [2702345.001]
  • [Cites] Brain Pathol. 1997 Apr;7(2):785-98 [9161729.001]
  • [Cites] Eur Radiol. 2006 Jan;16(1):180-6 [16402258.001]
  • [Cites] Radiology. 1999 Jun;211(3):791-8 [10352608.001]
  • (PMID = 17530237.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


80. Takata K, Gasparetto EL, Leite Cda C, Lucato LT, Reed UC, Matushita H, Aguiar PH, Rosemberg S: [Subependymal giant cell astrocytoma in patients with tuberous sclerosis: magnetic resonance imaging findings in ten cases]. Arq Neuropsiquiatr; 2007 Jun;65(2A):313-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Subependymal giant cell astrocytoma in patients with tuberous sclerosis: magnetic resonance imaging findings in ten cases].
  • [Transliterated title] Astrocitoma subependimário de células gigantes em pacientes com esclerose tuberosa: achados em ressonância magnética de dez casos.
  • OBJECTIVE: To report the magnetic resonance imaging (MRI) findings in 10 patients with subependimal giant cell astrocytoma (SGCA) and tuberous sclerosis (TS).
  • All patients underwent MRI, which was analyzed by two radiologists, final diagnosis was reached by consensus.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cerebral Ventricles / pathology. Tuberous Sclerosis / pathology


81. Liu BL, Cheng JX, Zhang X, Zhang W: Controversies concerning the application of brachytherapy in central nervous system tumors. J Cancer Res Clin Oncol; 2010 Feb;136(2):173-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Brachytherapy (BRT) is defined as a therapy technique where a radioactive source is placed a short distance from or within the tumor being treated.
  • Despite all the negative aspects, BRT continues to be conducted for the management of CNS tumors including gliomas, meningiomas and brain metastases.
  • [MeSH-major] Brachytherapy. Brain Neoplasms / radiotherapy. Radioisotopes / therapeutic use
  • [MeSH-minor] Astrocytoma / radiotherapy. Confounding Factors (Epidemiology). Dose Fractionation. Dose-Response Relationship, Radiation. Glioblastoma / radiotherapy. Humans. Oligodendroglioma / radiotherapy. Radiosurgery. Radiotherapy Dosage. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Retrospective Studies. Selection Bias. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8863-9 [16314646.001]
  • [Cites] Neurosurgery. 1996 Apr;38(4):696-701; discussion 701-2 [8692387.001]
  • [Cites] Br J Neurosurg. 1995;9(5):593-603 [8561931.001]
  • [Cites] NCI Monogr. 1988;(6):279-84 [3281031.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2006 Mar;18(2):93-103 [16523808.001]
  • [Cites] Radiology. 1979 Sep;132(3):727-30 [472255.001]
  • [Cites] J Nucl Med. 1998 Jul;39(7):1148-54 [9669385.001]
  • [Cites] Cancer. 1993 Jul 1;72 (1):190-5 [8508405.001]
  • [Cites] J Neurosurg. 1991 Nov;75(5):740-6 [1919696.001]
  • [Cites] Cancer. 1979 Oct;44(4):1256-72 [387205.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] J Neurosurg. 1984 Jan;60(1):61-8 [6358430.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1114-20 [12419438.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(11):1253-8 [11201640.001]
  • [Cites] Neurosurg Clin N Am. 1999 Apr;10(2):157-66 [10099087.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):287-95 [9457811.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):631-40 [14751537.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):319-26; discussion 326-8 [10690720.001]
  • [Cites] Strahlenther Onkol. 2003 Aug;179(8):509-20 [14509949.001]
  • [Cites] Cancer Res. 1981 Mar;41(3):845-9 [7459870.001]
  • [Cites] N Engl J Med. 1991 May 23;324(21):1471-6 [1822669.001]
  • [Cites] BMC Cancer. 2007 Aug 30;7:167 [17760992.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Jun;18(6):1421-7 [2370192.001]
  • [Cites] J Neurooncol. 1999 Aug;44(1):53-7 [10582669.001]
  • [Cites] Acta Neurochir Suppl. 1995;63:25-8 [7502723.001]
  • [Cites] Tumori. 1994 Feb 28;80(1):44-9 [8191598.001]
  • [Cites] Duodecim. 1995;111(21):2028-37 [9841160.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):541-7 [8655378.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):338-44 [15937907.001]
  • [Cites] J Neurosurg. 2006 Sep;105(3):375-84 [16961129.001]
  • [Cites] Neurosurgery. 2002 Aug;51(2):343-55; discussion 355-7 [12182772.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):291-8 [10802351.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1005-11 [9719109.001]
  • [Cites] J Neurosurg. 1987 Dec;67(6):864-73 [3316532.001]
  • [Cites] Neurosurg Focus. 2007 Mar 15;22(3):E3 [17608356.001]
  • [Cites] J Neurosurg. 1989 Jun;70(6):853-61 [2715812.001]
  • [Cites] Strahlenther Onkol. 2000 Jun;176(6):259-64 [10897252.001]
  • [Cites] Pediatr Neurosurg. 1996 Sep;25(3):109-15 [9144708.001]
  • [Cites] Biophys J. 1979 Oct;28(1):81-91 [262446.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] J Neurosurg. 1992 Feb;76(2):179-83 [1730945.001]
  • [Cites] Neurosurgery. 2002 Jan;50(1):41-6; discussion 46-7 [11844233.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):159-65 [17331666.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1389-97 [11870184.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Jul;11(7):1367-73 [4008293.001]
  • [Cites] Recent Results Cancer Res. 1994;135:117-25 [8047687.001]
  • [Cites] Neurosurgery. 2000 May;46(5):1123-8; discussion 1128-30 [10807244.001]
  • [Cites] Neurosurgery. 1995 Mar;36(3):467-73 [7753345.001]
  • [Cites] Tumori. 1996 Jul-Aug;82(4):339-44 [8890967.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):687-92 [10524423.001]
  • [Cites] J Neurooncol. 2005 May;73(1):71-86 [15933821.001]
  • [Cites] Neurosurgery. 1991 Nov;29(5):676-80 [1961396.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):1167-76 [7607939.001]
  • [Cites] Med Pediatr Oncol. 1994;22(3):173-80 [8272006.001]
  • [Cites] Br J Radiol. 1999 Aug;72 (860):805-8 [10624349.001]
  • [Cites] Strahlenther Onkol. 2002 Jan;178(1):10-7 [11977386.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):719-27 [8040017.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):275-82; discussion 282-4 [7731507.001]
  • [Cites] Br J Radiol. 1995 Feb;68(806):175-81 [7537597.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1133-9 [15990019.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):921-6 [10098448.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(4):657-67 [1429088.001]
  • [Cites] Strahlenther Onkol. 2007 Oct;183(10 ):563-70 [17896088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Sep;6(9):1215-28 [7007303.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(2):127-33 [10189493.001]
  • [Cites] Neurosurgery. 1987 Jun;20(6):938-45 [3614575.001]
  • [Cites] J Neurosurg. 2003 Aug;99(2):297-303 [12924704.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):601-6 [1651302.001]
  • [Cites] J Neurosurg. 2000 Dec;93(6):917-26 [11117863.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 May 20;26(2):239-44 [8387988.001]
  • [Cites] Radiology. 1978 Oct;129(1):195-8 [693874.001]
  • [Cites] Cancer. 1995 Feb 15;75(4):1051-9 [7842408.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(4):583-91 [1429079.001]
  • [Cites] Stereotact Funct Neurosurg. 1992;59(1-4):183-92 [1295039.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):72-7 [10413158.001]
  • [Cites] Radiother Oncol. 1997 Jun;43(3):253-60 [9215784.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):931-41 [7607967.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):531-9 [7928483.001]
  • [Cites] J Neurooncol. 2004 Aug-Sep;69(1-3):83-100 [15527082.001]
  • [Cites] Neuro Oncol. 2004 Apr;6(2):119-26 [15134626.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Dec 1;30(5):1213-7 [7961031.001]
  • [Cites] Cancer. 2000 Jun 15;88(12):2796-802 [10870063.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Neurosurgery. 2006 Apr;58(4):701-9; discussion 701-9 [16575334.001]
  • [Cites] Eur J Cancer. 2004 May;40(7):1013-20 [15093576.001]
  • [Cites] Arch Neurol. 1995 Feb;52(2):162-7 [7848125.001]
  • [Cites] J Neurosurg. 1995 Mar;82(3):418-29 [7861220.001]
  • [Cites] Neuro Oncol. 2009 Feb;11(1):41-50 [18628405.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(4):853-61 [1319981.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • (PMID = 19956971.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radioisotopes
  • [Number-of-references] 21
  •  go-up   go-down


82. Sherwood PR, Donovan HS, Given CW, Lu X, Given BA, Hricik A, Bradley S: Predictors of employment and lost hours from work in cancer caregivers. Psychooncology; 2008 Jun;17(6):598-605
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of employment and lost hours from work in cancer caregivers.
  • Family caregivers (N=80) of persons with a primary malignant brain tumor participated in a 45-60 min telephone interview, answering questions regarding the impact of providing care on their emotional health and employment status.
  • Caregivers were more likely to report lost hours from work when care recipients required assistance with Instrumental Activities of Daily Living (IADLs) and were closer to the time of diagnosis.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Caregivers.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17957756.001).
  • [ISSN] 1099-1611
  • [Journal-full-title] Psycho-oncology
  • [ISO-abbreviation] Psychooncology
  • [Language] ENG
  • [Grant] United States / NINR NIH HHS / NR / F31 NR008069; United States / NINR NIH HHS / NR / F31NR8069
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS779536; NLM/ PMC4846278
  •  go-up   go-down


83. Combs SE, Ahmadi R, Schulz-Ertner D, Thilmann C, Debus J: Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation. J Neurooncol; 2005 Feb;71(3):319-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At primary diagnosis of the tumor, the histology was grade II astrocytoma, oligodendroglioma or oligoastrocytoma.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Dose Fractionation. Glioma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):996-1003 [14575830.001]
  • [Cites] Cancer. 1993 Jul 1;72 (1):190-5 [8508405.001]
  • [Cites] Eur J Cancer. 1998 Jan;34(1):98-102 [9624245.001]
  • [Cites] Cancer. 1994 Sep 15;74(6):1784-91 [8082081.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):145-51 [11285552.001]
  • [Cites] Arch Neurol. 1989 Nov;46(11):1238-9 [2818260.001]
  • [Cites] Arch Neurol. 1990 Oct;47(10):1138-40 [2222248.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):919-27 [3967199.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 May;64(5):581-7 [9598670.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):232-8 [12865907.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]
  • [Cites] J Neurosurg. 1989 Jun;70(6):853-61 [2715812.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9 [2542195.001]
  • [Cites] Semin Oncol. 1994 Apr;21(2):236-48 [8153667.001]
  • [Cites] Can J Surg. 1993 Jun;36(3):271-5 [8391917.001]
  • [Cites] Radiother Oncol. 2000 Nov;57(2):215-23 [11054526.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):393-8 [9069312.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1294-301 [9193320.001]
  • [Cites] Neurology. 2000 Apr 11;54(7):1402-3 [10751245.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):646-51 [12586801.001]
  • [Cites] Radiologe. 1995 Sep;35(9):583-6 [8588040.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):719-27 [8040017.001]
  • [Cites] J Neurosurg. 1984 Oct;61(4):665-73 [6470776.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12 ):2305-11 [12805331.001]
  • [Cites] Neurosurgery. 1987 Nov;21(5):615-21 [2827052.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1133-41 [10613305.001]
  • [Cites] J Neurosurg. 1993 Jun;78(6):909-14 [8487073.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):370-9 [9010111.001]
  • [Cites] Oncology. 2000 Feb;58(2):108-16 [10705237.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):977-82 [10192343.001]
  • [Cites] Neurology. 1999 Sep 22;53(5):1141-3 [10496285.001]
  • [Cites] Ann Oncol. 2003 Apr;14 (4):599-602 [12649108.001]
  • [Cites] Semin Surg Oncol. 2001 Jan-Feb;20(1):13-23 [11291128.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):10-4 [14765378.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):291-6 [8795601.001]
  • [Cites] Neurology. 2000 Apr 11;54(7):1442-8 [10751254.001]
  • [Cites] Clin Neurosurg. 1995;42:488-94 [8846613.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Neurosurgery. 1996 May;38(5):872-8; discussion 878-9 [8727811.001]
  • [Cites] Radiology. 1996 Oct;201(1):275-8 [8816559.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1937-45 [8137221.001]
  • (PMID = 15735924.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Zou W, Wang Z, Liu Y, Fan Y, Zhou BY, Yang XF, He JJ: Involvement of p300 in constitutive and HIV-1 Tat-activated expression of glial fibrillary acidic protein in astrocytes. Glia; 2010 Oct;58(13):1640-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we reported concurrent up-regulation of adenovirus E1a-associated 300 kDa protein p300 and GFAP in Tat-expressing human astrocytoma cells and primary astrocytes.

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TRITIUM, RADIOACTIVE .
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • [Cites] Neurochem Res. 2000 Oct;25(9-10):1439-51 [11059815.001]
  • [Cites] Mol Cell Neurosci. 2004 Nov;27(3):296-305 [15519244.001]
  • [Cites] Nat Med. 2000 Dec;6(12):1380-7 [11100124.001]
  • [Cites] J Immunol. 2000 Dec 15;165(12):7171-9 [11120849.001]
  • [Cites] Nat Genet. 2001 Jan;27(1):117-20 [11138011.001]
  • [Cites] Blood. 2001 Jan 15;97(2):352-8 [11154208.001]
  • [Cites] FEBS Lett. 2001 Feb 2;489(2-3):139-43 [11165238.001]
  • [Cites] J Leukoc Biol. 2002 Apr;71(4):545-56 [11927640.001]
  • [Cites] J Virol. 2002 May;76(9):4526-35 [11932418.001]
  • [Cites] J Biol Chem. 2002 Jun 21;277(25):22215-21 [11956210.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39312-9 [12167619.001]
  • [Cites] Mol Cell. 2004 Jul 2;15(1):83-94 [15225550.001]
  • [Cites] Biochem Pharmacol. 2004 Sep 15;68(6):1145-55 [15313412.001]
  • [Cites] Cell. 1988 Dec 23;55(6):1189-93 [2849510.001]
  • [Cites] Brain Pathol. 1994 Jul;4(3):259-75 [7952267.001]
  • [Cites] Neuron. 1995 Jan;14(1):29-41 [7826639.001]
  • [Cites] Neurochem Res. 2004 Nov;29(11):2075-93 [15662842.001]
  • [Cites] J Biol Chem. 2005 Mar 11;280(10):9390-9 [15611041.001]
  • [Cites] Exp Neurol. 2005 May;193(1):218-27 [15817280.001]
  • [Cites] Front Biosci. 2006;11:708-17 [16146763.001]
  • [Cites] J Neurovirol. 2006 Feb;12(1):17-24 [16595370.001]
  • [Cites] J Neurosci. 2006 Apr 12;26(15):4054-62 [16611822.001]
  • [Cites] J Neurochem. 2006 Jul;98(1):146-55 [16805804.001]
  • [Cites] Curr HIV Res. 2006 Jul;4(3):249-57 [16842078.001]
  • [Cites] Exp Neurol. 2006 Sep;201(1):193-202 [16750528.001]
  • [Cites] Virology. 2006 Sep 30;353(2):247-57 [16843515.001]
  • [Cites] Virology. 2006 Nov 25;355(2):152-63 [16908043.001]
  • [Cites] J Immunol. 2007 Jan 15;178(2):869-76 [17202348.001]
  • [Cites] Am J Pathol. 2007 Dec;171(6):1923-35 [18055541.001]
  • [Cites] Mol Pharmacol. 2008 May;73(5):1424-33 [18276775.001]
  • [Cites] J Pathol. 2008 Dec;216(4):521-32 [18798221.001]
  • [Cites] J Cereb Blood Flow Metab. 2010 Mar;30(3):522-33 [19794400.001]
  • [Cites] J Neuroimmune Pharmacol. 2011 Mar;6(1):121-9 [20414733.001]
  • [Cites] BMC Biochem. 2002 Jun 10;3:14 [12069692.001]
  • [Cites] J Neurochem. 2003 Jan;84(1):169-79 [12485413.001]
  • [Cites] J Immunol. 2003 Mar 1;170(5):2629-37 [12594291.001]
  • [Cites] J Biol Chem. 2003 Apr 11;278(15):13512-9 [12551932.001]
  • [Cites] Am J Pathol. 2003 May;162(5):1693-707 [12707054.001]
  • [Cites] Neurosci Lett. 2004 Apr 15;359(3):155-8 [15050687.001]
  • [Cites] Novartis Found Symp. 2004;259:182-93; discussion 193-6, 223-5 [15171254.001]
  • [Cites] Anal Biochem. 1995 May 1;227(1):168-75 [7668378.001]
  • [Cites] Neuron. 1996 Oct;17(4):607-15 [8893019.001]
  • [Cites] AIDS. 1997 Oct;11(12):1421-31 [9342064.001]
  • [Cites] Am J Pathol. 1998 Feb;152(2):391-8 [9466565.001]
  • [Cites] Exp Cell Res. 1998 Mar 15;239(2):332-43 [9521851.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Jun;57(6):563-70 [9630236.001]
  • [Cites] J Neurosci Res. 1998 Aug 1;53(3):353-60 [9698163.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13519-24 [9811832.001]
  • [Cites] Science. 1999 Apr 16;284(5413):479-82 [10205054.001]
  • [Cites] Curr Opin Genet Dev. 1999 Apr;9(2):140-7 [10322133.001]
  • [Cites] Braz J Med Biol Res. 1999 May;32(5):619-31 [10412574.001]
  • [Cites] J Infect Dis. 2000 Dec;182(6):1643-51 [11069235.001]
  • (PMID = 20578042.001).
  • [ISSN] 1098-1136
  • [Journal-full-title] Glia
  • [ISO-abbreviation] Glia
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01NS039804; United States / NIDA NIH HHS / DA / R21 DA029428; United States / NINDS NIH HHS / NS / R01NS065785; United States / NIMH NIH HHS / MH / R01 MH092673; United States / NINDS NIH HHS / NS / R01 NS065785; United States / NINDS NIH HHS / NS / R01 NS039804
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EGR1 protein, human; 0 / Early Growth Response Protein 1; 0 / Glial Fibrillary Acidic Protein; 0 / RNA, Small Interfering; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / tat Gene Products, Human Immunodeficiency Virus; 10028-17-8 / Tritium; 147336-22-9 / Green Fluorescent Proteins; 298-93-1 / thiazolyl blue; EC 2.3.1.48 / E1A-Associated p300 Protein; EC 2.3.1.48 / EP300 protein, human; EC 3.2.1.23 / beta-Galactosidase; VC2W18DGKR / Thymidine
  • [Other-IDs] NLM/ NIHMS209233; NLM/ PMC2919602
  •  go-up   go-down


85. Grau SJ, Trillsch F, Herms J, Thon N, Nelson PJ, Tonn JC, Goldbrunner R: Expression of VEGFR3 in glioma endothelium correlates with tumor grade. J Neurooncol; 2007 Apr;82(2):141-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of VEGFR3 in glioma endothelium correlates with tumor grade.
  • While VEGFR2 is thought to play a central role in tumor angiogenesis, anti-angiogenic therapies targeting VEGFR2 in glioma models can show escape phenomena with secondary onset of angiogenesis.
  • The purpose of this study was to find explanations for these processes by searching for alternative pathways regulating glioma angiogenesis and reveal a correlation with tumor grade.
  • Thus, VEGFR3, which is not expressed in normal brain, and its ligands VEGF-C and -D, were assessed in high grade (WHO degrees IV, glioblastomas, GBM) and low grade gliomas [WHO degrees II astrocytomas (AII)].
  • In all GBM, a strong protein expression of VEGFR3 was found on tumor endothelium, VEGF-C and -D expression was found on numerous cells in areas of high vascularization.
  • On RNA level, a significant up-regulation of VEGFR3 was detected in GBM compared to AII and non-neoplastic brain.
  • In AII, only very moderate VEGFR3, VEGF-C and -D expression was found on protein and RNA level indicating a correlation of VEGFR3 expression with tumor grade.
  • The demonstration of a complete angiogenic signaling system that is dependent on tumor grade may influence the traditional paradigm of glioma angiogenesis and may provide a basis for more effective anti-angiogenic treatment strategies.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Endothelium, Vascular / metabolism. Vascular Endothelial Growth Factor Receptor-3 / metabolism
  • [MeSH-minor] Adult. Aged. Antigens, CD31 / metabolism. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic. Tumor Cells, Cultured. Vascular Endothelial Growth Factor C / metabolism. Vascular Endothelial Growth Factor D / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest Ophthalmol Vis Sci. 2002 Mar;43(3):849-57 [11867607.001]
  • [Cites] Mol Med. 2001 Sep;7(9):598-608 [11778649.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8548-53 [15623638.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):527-37 [16330026.001]
  • [Cites] Oncologist. 2005 Jun-Jul;10(6):382-91 [15967832.001]
  • [Cites] J Histochem Cytochem. 2002 Jun;50(6):767-77 [12019293.001]
  • [Cites] Microsc Res Tech. 2004 Jun 15;64(3):279-86 [15452895.001]
  • [Cites] EMBO J. 2001 Sep 3;20(17):4762-73 [11532940.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):219-27 [12086857.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Nov 12;324(2):909-15 [15474514.001]
  • [Cites] Blood. 2003 Jan 1;101(1):168-72 [12393704.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1525-32 [16533777.001]
  • [Cites] FASEB J. 2001 Apr;15(6):1028-36 [11292664.001]
  • [Cites] J Histochem Cytochem. 2003 Mar;51(3):331-8 [12588961.001]
  • [Cites] Science. 1998 Oct 30;282(5390):946-9 [9794766.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jun;19(6):648-54 [15151619.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):999-1004 [15939715.001]
  • [Cites] Placenta. 2000 Mar-Apr;21 Suppl A:S11-5 [10831116.001]
  • [Cites] Int J Cancer. 2004 Aug 20;111(2):184-91 [15197769.001]
  • [Cites] Pathol Res Pract. 2005;201(2):93-9 [15901129.001]
  • [Cites] Eur J Cancer. 2002 Jul;38(10):1413-9 [12091074.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):887-91 [10970690.001]
  • [Cites] Histol Histopathol. 2005 Jan;20(1):155-75 [15578435.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1823-9 [10430087.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):553-63 [15607960.001]
  • [Cites] J Biol Chem. 2004 Aug 20;279(34):36148-57 [15215251.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3619-23 [16101190.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2002;67:189-96 [12858540.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):180-5 [10697276.001]
  • [Cites] J Pathol. 2001 Nov;195(4):490-7 [11745682.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1367-74 [12393458.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7171-8 [15534089.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3731-6 [15172975.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 29;333(2):328-35 [15961063.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5137-44 [15297417.001]
  • [Cites] Ann Endocrinol (Paris). 2000 Feb;61(1):70-4 [10790595.001]
  • [Cites] J Neurooncol. 2006 Jan;76(1):39-48 [16155723.001]
  • [Cites] Kidney Int. 2002 Jan;61(1):133-40 [11786093.001]
  • [Cites] J Biol Chem. 1996 Nov 8;271(45):28220-8 [8910439.001]
  • [Cites] Clin Breast Cancer. 2003 Dec;4(5):354-60 [14715111.001]
  • [Cites] Ann N Y Acad Sci. 2002 Dec;979:120-30 [12543722.001]
  • [Cites] J Med Chem. 2005 Mar 10;48(5):1359-66 [15743179.001]
  • [Cites] Blood. 2000 Jul 15;96(2):546-53 [10887117.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6020-4 [11507045.001]
  • [Cites] Angiogenesis. 2005;8(3):263-71 [16328159.001]
  • [Cites] J Biol Chem. 2003 Oct 17;278(42):40973-9 [12881528.001]
  • [Cites] J Neurooncol. 2000 Oct-Nov;50(1-2):149-63 [11245274.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14389-94 [9826710.001]
  • [Cites] Recent Prog Horm Res. 2000;55:15-35; discussion 35-6 [11036931.001]
  • [Cites] J Pathol. 2006 May;209(1):34-43 [16523449.001]
  • (PMID = 17115285.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / VEGFC protein, human; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-3
  •  go-up   go-down


86. Qu M, Olofsson T, Sigurdardottir S, You C, Kalimo H, Nistér M, Smits A, Ren ZP: Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas. Acta Neuropathol; 2007 Feb;113(2):129-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas.
  • Oligoastrocytomas are glial tumours consisting of a mixture of neoplastic astrocytic and oligodendroglial cells.
  • To investigate whether these neoplastic cell types in oligoastrocytomas have different genetic profiles, we examined the two different components of oligoastrocytomas in comparison with the histological diagnosis of the specific tumour area for LOH 1p/19q and TP53 mutations by using microdissection technique.
  • We found a variety of lost markers for 1p and 19q, and the presence of two different TP53 mutations in the tumour samples.
  • In the majority of cases (9/11), the oligodendroglial and astrocytic components of an individual oligoastrocytoma displayed the same genotype.
  • We present two cases of biphasic oligoastrocytomas with aberrant findings, suggesting the coexistence of genetically and morphologically distinct tumour cell clones in these tumours.
  • In one case, the oligodendroglial part of the tumour showed LOH19q, whereas the astrocytic part showed TP53 mutation (codon 273).
  • In another case, we found LOH 1p/19q in the oligodendroglial component, but two retained areas on chromosome 1p in the astrocytic component of the tumour.
  • No evidence was found for the coexistence of tumour cells with the two genotypical changes within the same morphological region of one individual tumour.
  • The two cases of biphasic oligoastrocytomas in our sample that display a different genotype in the astrocytic and oligodendroglial part of the tumour show that different components of an oligoastrocytoma may be derived from different cell clones during neoplastic transformation.
  • [MeSH-major] Astrocytoma / classification. Astrocytoma / genetics. Brain Neoplasms / classification. Brain Neoplasms / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 1 / genetics. Female. Humans. Male. Microsatellite Repeats. Middle Aged. Mutation. Reverse Transcriptase Polymerase Chain Reaction / methods. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17031656.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


87. Mishra MK, Kumawat KL, Basu A: Japanese encephalitis virus differentially modulates the induction of multiple pro-inflammatory mediators in human astrocytoma and astroglioma cell-lines. Cell Biol Int; 2008 Dec;32(12):1506-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Japanese encephalitis virus differentially modulates the induction of multiple pro-inflammatory mediators in human astrocytoma and astroglioma cell-lines.
  • We have shown that Japanese encephalitis virus (JEV) infection causes morphological and functional changes in astrocytic cell-lines.
  • [MeSH-major] Astrocytes / immunology. Brain / immunology. Encephalitis, Japanese / immunology. Gliosis / immunology. Oxidative Stress / immunology
  • [MeSH-minor] Animals. Animals, Newborn. Astrocytoma / immunology. Brain Neoplasms / immunology. Cell Line, Transformed. Cell Line, Tumor. Ceruloplasmin / immunology. Ceruloplasmin / metabolism. Chemokines / immunology. Chemokines / metabolism. Cytokines / immunology. Cytokines / metabolism. Encephalitis Virus, Japanese / immunology. Humans. Mice. Mice, Inbred BALB C. Reactive Oxygen Species / immunology. Reactive Oxygen Species / metabolism. Thioredoxins / immunology. Thioredoxins / metabolism. Vesicular Glutamate Transport Proteins / immunology. Vesicular Glutamate Transport Proteins / metabolism

  • Genetic Alliance. consumer health - Japanese encephalitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18801452.001).
  • [ISSN] 1095-8355
  • [Journal-full-title] Cell biology international
  • [ISO-abbreviation] Cell Biol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokines; 0 / Cytokines; 0 / Reactive Oxygen Species; 0 / Vesicular Glutamate Transport Proteins; 52500-60-4 / Thioredoxins; EC 1.16.3.1 / Ceruloplasmin
  •  go-up   go-down


88. Raju GP, Urion DK, Sahin M: Neonatal subependymal giant cell astrocytoma: new case and review of literature. Pediatr Neurol; 2007 Feb;36(2):128-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neonatal subependymal giant cell astrocytoma: new case and review of literature.
  • Subependymal giant cell astrocytomas are one of the three major intracranial lesions found in tuberous sclerosis complex.
  • This report investigates an extremely large neonatal subependymal giant cell astrocytoma which was initially identified in utero at 19 weeks of gestation in a high-risk pregnancy with no family history of tuberous sclerosis complex.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Infant, Newborn. Pregnancy. Pregnancy, High-Risk. Prenatal Diagnosis. Tuberous Sclerosis


89. Birca A, Mercier C, Major P: Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex. J Neurosurg Pediatr; 2010 Oct;6(4):381-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intracranial hypertension can be caused by SEGAs due to their propensity to block the foramen of Monro.
  • The traditional management approach is to monitor SEGAs with periodic neuroimaging and to resect those that exhibit serial growth and/or cause clinical signs of intracranial hypertension.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Sirolimus / administration & dosage. Tuberous Sclerosis / complications


90. Zhang W, Zhao J, Guo D, Zhong W, Shu J, Luo Y: [Application of susceptibility weighted imaging in revealing intratumoral blood products and grading gliomas]. J Radiol; 2010 Apr;91(4):485-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Blood Proteins / analysis. Brain Neoplasms / diagnosis. Glioma / diagnosis. Image Processing, Computer-Assisted / methods. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Astrocytoma / diagnosis. Astrocytoma / pathology. Female. Glioblastoma / diagnosis. Glioblastoma / pathology. Hemorrhage / diagnosis. Hemorrhage / pathology. Humans. Male. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514004.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Blood Proteins
  •  go-up   go-down


91. Kasprzak HA, Trojan J, Bierwagen M, Kopiński P, Jarocki P, Bartczak K, Czapiewska J: [Usefulness of the antisense and triplex anti-IGF-1 techniques for postoperative cellular gene therapy of malignant gliomas expressing IGF-1]. Neurol Neurochir Pol; 2006 Nov-Dec;40(6):509-15; discussion 516
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Usefulness of the antisense and triplex anti-IGF-1 techniques for postoperative cellular gene therapy of malignant gliomas expressing IGF-1].
  • BACKGROUND AND PURPOSE: The aim of the study was to estimate the usefulness of the antineoplastic vaccination in treatment of malignant brain tumors.
  • MATERIAL AND METHODS: Between 2001 and 2005, ten patients suffering from malignant glial tumors were treated.
  • The histopathological examination showed 4 cases of glioblastoma and 6 cases of anaplastic astrocytoma.
  • Initially, patients were operated on with dissection of 1 cm(3) of the most representative part of tumor.
  • The neoplasm cells were cultured, transfected with episomal pMT EP vector (expressing alternatively oligonucleotide sequence forming triple helix with IGF-I gene or antisense against IGF-1 mRNA), re-cultured, irradiated and resuspended in medium to prepare antineoplastic vaccine.
  • This gene therapy needs further investigations as a method of oncological monotherapy of brain malignant gliomas.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / therapy. Genetic Therapy. Glioma / genetics. Glioma / therapy. Insulin-Like Growth Factor I / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17199177.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Oligonucleotides, Antisense; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


92. Gupta B, Torchilin VP: Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol Immunother; 2007 Aug;56(8):1215-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice.
  • Liposomes, modified with monoclonal antibodies, are suitable carriers for targeted delivery of chemotherapeutic drugs into brain tumors.
  • Here, we investigate the therapeutic efficacy of monoclonal anticancer antibody 2C5-modified long-circulating liposomes (LCL) loaded with doxorubicin (2C5-DoxLCL) for the treatment of U-87 MG human brain tumors in an intracranial model in nude mice.
  • In vitro, 2C5-DoxLCL is significantly more effective in killing the U-87 MG tumor cells than Doxil (commercial doxorubicin-loaded PEGylated LCL) or DoxLCL modified with a non-specific IgG.
  • The treatment of intracranial U-87 MG brain tumors in nude mice with 2C5-DoxLCL provides a significant therapeutic benefit over control formulations, substantially reducing the tumor size and almost doubling the survival time.
  • Thus, monoclonal antibody 2C5-modified LCL can specifically target the anticancer drugs to brain tumors, leading to improved therapeutic treatment of brain tumor in an intracranial model, in vivo.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Doxorubicin / therapeutic use. Immunoconjugates / therapeutic use
  • [MeSH-minor] Animals. Apoptosis. Cell Line, Tumor. Cerebral Cortex. Drug Delivery Systems. Female. Humans. Injections. Injections, Subcutaneous. Liposomes / administration & dosage. Mice. Mice, Nude. Nucleosomes / immunology. Polyethylene Glycols / administration & dosage. Tumor Burden. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17219149.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL55519
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Immunoconjugates; 0 / Liposomes; 0 / Nucleosomes; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin
  •  go-up   go-down


93. Idbaih A, Boisselier B, Marie Y, El Hallani S, Sanson M, Crinière E, Rodero M, Carpentier C, Paris S, Laigle-Donadey F, Ducray F, Hoang-Xuan K, Delattre JY: TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors. Cancer Genet Cytogenet; 2007 Sep;177(2):103-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Such results were also reported in brain tumors, notably in astrocytomas.
  • We retrospectively analyzed blood samples of 275 oligodendroglial tumor patients for the TP53 codon 72 polymorphism and compared them with a series of 144 healthy controls.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Codon. Oligodendroglioma / genetics. Polymorphism, Genetic / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Astrocytoma / genetics. Astrocytoma / metabolism. Case-Control Studies. DNA, Neoplasm / blood. DNA, Neoplasm / genetics. DNA, Neoplasm / metabolism. Female. Genotype. Glioma / genetics. Glioma / metabolism. Humans. Immunoenzyme Techniques. Male. Microsatellite Repeats. Middle Aged. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17854663.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


94. Paixão Becker A, de Oliveira RS, Saggioro FP, Neder L, Chimelli LM, Machado HR: In pursuit of prognostic factors in children with pilocytic astrocytomas. Childs Nerv Syst; 2010 Jan;26(1):19-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common site of tumor formation was the cerebellum (17), followed by brainstem (4), optic chiasmatic hypothalamic region (4), cerebral hemisphere (3), cervical spinal cord (2), and optic nerve (1).
  • Gross total resection (GTR) was achieved in 23 (74.1%), mainly in those with tumors located in the cerebellum and cerebral hemispheres (P = 0.02).
  • In all cases, Gal-3 expression in tumor cells was